###begin article-title 0
###xml 101 104 101 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
Identification of Apurinic/apyrimidinic endonuclease 1 (APE1) as the endoribonuclease that cleaves c-myc mRNA
###end article-title 0
###begin p 1
###xml 69 72 69 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 126 129 126 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 151 153 151 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 165 168 165 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 314 322 314 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 533 536 533 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 947 950 947 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 1111 1114 1111 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 1264 1267 1264 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 250 253 <span type="species:ncbi:10116">rat</span>
###xml 772 777 <span type="species:ncbi:9606">human</span>
Endonucleolytic cleavage of the coding region determinant (CRD) of c-myc mRNA appears to play a critical role in regulating c-myc mRNA turnover. Using 32P-labeled c-myc CRD RNA as substrate, we have purified and identified two endoribonucleases from rat liver polysomes that are capable of cleaving the transcript in vitro. A 17-kDa enzyme was identified as RNase1. Apurinic/apyrimidinic (AP) DNA endonuclease 1 (APE1) was identified as the 35-kDa endoribonuclease that preferentially cleaves in between UA and CA dinucleotides of c-myc CRD RNA. APE1 was further confirmed to be the 35-kDa endoribonuclease because: (i) the endoribonuclease activity of the purified 35-kDa native enzyme was specifically immuno-depleted with APE1 monoclonal antibody, and (ii) recombinant human APE1 generated identical RNA cleavage patterns as the native liver enzyme. Studies using E96A and H309N mutants of APE1 suggest that the endoribonuclease activity for c-myc CRD RNA shares the same active center with the AP-DNA endonuclease activity. Transient knockdown of APE1 in HeLa cells led to increased steady-state level of c-myc mRNA and its half-life. We conclude that the ability to cleave RNA dinucleotides is a previously unidentified function of APE1 and it can regulate c-myc mRNA level possibly via its endoribonuclease activity.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 288 289 284 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 305 306 298 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 311 314 304 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 316 317 309 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 318 319 311 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 322 325 315 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR</italic>
###xml 328 329 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 351 352 344 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 405 407 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 658 659 651 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 332 349 <span type="species:ncbi:10407">hepatitis B virus</span>
In higher eukaryotes, including mammals, endonucleolytic cleavage intermediates were shown to be generated during decay of a number of mRNAs (1). For instance, mRNA decay intermediates have been described for the transferrin receptor (2), insulin-like growth factor II (3), alpha-globin (4), beta-globin (5), c-myc (6,7), MDR1 (8), hepatitis B virus (9) and mRNAs containing premature termination codons (10). For most systems, the responsible endoribonuclease has not been identified. This is in part due to the difficulty in identifying this group of enzymes which so far appeared to be substrate-specific and have no sequence homology to known nucleases (1).
###end p 3
###begin p 4
###xml 415 418 415 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 573 574 569 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 609 611 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 623 625 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 698 700 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 718 720 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 765 767 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 768 770 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 847 849 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 850 852 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 407 412 <span type="species:ncbi:10090">mouse</span>
To fully understand the mechanism and significance of endonucleolytic cleavage in the control of mRNA degradation and abundance, the responsible endoribonuclease must be identified and characterized. To date, endoribonucleases that have been shown to cleave vertebrate mRNA are: Ras GTPase-activating protein-SH3 domain binding protein (G3BP) that cleaves between cytosine and adenine residues at 3' UTR of mouse c-myc mRNA (11), an estrogen-regulated polysomal endoribonuclease termed PMR1 that cleaves albumin and vitellogenin mRNAs (12), ErEN that cleaves alpha-globin (4), activator of RNA Decay (ARD-1) (13), RNase L (14), endoplasmic reticulum-associated type 1 transmembrane protein (IRE1) (15) and Argonaute2 (16). Rrp44, a component of eukaryotic exosome (17,18), and SMG6, a protein involved in metazoan nonsense-mediated decay pathway (19,20), have recently demonstrated to possess endonucleolytic activity. Such surprising findings underscore the significance of endonucleolytic cleavage and suggest that this mode of RNA cleavage to control mRNA decay should be re-examined.
###end p 4
###begin p 5
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 116 119 116 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 295 298 295 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 383 391 383 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 501 504 501 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 531 534 531 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 795 798 795 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 859 862 859 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 888 893 888 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25 B26 B27 B28 B29">25&#8211;29</xref>
###xml 951 954 951 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 989 990 989 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 991 992 991 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1134 1137 1134 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 1336 1339 1336 1339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 1345 1353 1345 1353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1405 1408 1405 1408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 1434 1441 1434 1441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 90 95 <span type="species:ncbi:9606">human</span>
The proto-oncogene c-Myc has been implicated in the development of virtually all types of human cancers (21). The c-myc mRNA can be degraded via two distinct pathways. One pathway involves deadenylation followed by 3'-5' exonucleolytic degradation catalyzed by 3'-5'exoribonucleases (22). The c-myc mRNA can also be degraded endonucleolytically, as discovered using a polysome-based in vitro mRNA decay assay (23). An endoribonuclease is believed to target the exposed region of polysome-associated c-myc mRNA referred to as the c-myc coding region determinant or CRD. Indeed, recent evidence suggests that translational pausing at the CRD could result in a ribosome-deficient region that is susceptible to endonucleolytic attack (24). Several studies have confirmed that the coding region of c-myc mRNA, including the CRD, is involved in the regulation of c-myc mRNA stability in cells (25-29). Furthermore, endonucleolytic decay intermediates for c-myc mRNA have been detected in cells (6,7), which provided further support for the significance of endonucleolytic cleavage. However, the endoribonuclease(s) that can cleave CRD of c-myc mRNA remained to be identified. Here, we describe the identification of the apurinic/apyrimidinic (AP) DNA endonuclease 1 (APE1), also referred to as Ref-1, as an endoribonuclease that can cleave c-myc mRNA in vitro. We further show that APE1 could in fact control c-myc mRNA level and half-life in vivo.
###end p 5
###begin title 6
MATERIALS AND METHODS
###end title 6
###begin title 7
###xml 27 30 <span type="species:ncbi:10116">rat</span>
Purification of the native rat liver endoribonucleases
###end title 7
###begin p 8
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 589 591 589 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 603 606 603 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 853 855 847 849 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 867 870 861 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 64 67 <span type="species:ncbi:10116">rat</span>
The native endoribonucleases were purified from juvenile frozen rat livers as previously described (30) except for the following changes: (i) Reactive blue-4 chromatographic step was omitted, (ii) dialysis rather than dilution was performed at each step to remove excess KCl, (iii) Superdex 75 Hi Load 16/60 (GE Healthcare, Quebec) gel filtration was used as the last preparative step and (iv) RNasin was omitted in the standard endoribonuclease assay. One unit (U) of enzyme was defined as the quantity of purified enzyme (up to heparin-Sepharose column) required to cleave 90 fmol of 5'-32P-labeled c-myc CRD RNA substrate in 5 min at 37degreesC under the standard endoribonuclease assay described below. For gel filtration purified enzyme, 1 U of 10-20-kDa or 30-40-kDa enzyme was defined as the amount of the enzyme required to cleave 90 fmol of 5'-32P-labeled c-myc CRD RNA substrate under conditions as described above.
###end p 8
###begin title 9
Preparation of radiolabeled nucleic acids
###end title 9
###begin p 10
###xml 22 25 22 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 118 126 118 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 212 214 208 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 253 255 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 256 258 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 441 444 437 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 539 541 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 574 576 566 568 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 634 642 626 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in-vitro</italic>
###xml 730 732 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 733 735 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 801 804 793 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 14 19 <span type="species:ncbi:9606">human</span>
To synthesize human c-myc CRD RNA corresponding to nts 1705-1792, the plasmid pGEM4Z-myc 1705-1792 was linearized and in vitro transcribed as previously described (30,31). The RNA was then 5'-labeled with gamma-[32P]-ATP using T4 polynucleotide kinase (30,31). This RNA substrate was used throughout this study unless otherwise indicated. For confirming recombinant APE1 as an endoribonuclease, PCR-amplified DNA template corresponding to c-myc CRD nts 1730-1766 was used to transcribe RNA using T7 RNA polymerase as previously described (30). For internal labeling, alpha-[32P]-UTP was used during transcription. For 5'end labeling, in-vitro transcribed RNA was 5'-labeled using T4 polynucleotide kinase as described previously (30,31). The oligonucleotide 5'CAAGGTAGTrUATCCTTG-3' corresponding to c-myc CRD nts 1742-1757 (synthesized by IDT Inc.) was also 5'-labeled and used as substrate in the endoribonuclease assay.
###end p 10
###begin title 11
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro endoribonuclease assay and mapping of RNA cleavage sites
###end title 11
###begin p 12
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 263 265 262 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 291 292 278 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1619 1621 1581 1583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
The standard endoribonuclease assay has been described previously (30,31). The standard 20-mul reaction mixture used for this assay included 2 mM DTT, 1.0 U of RNasin, 2 mM magnesium acetate, 50 mM potassium acetate, 0.1 mM spermidine, 350 fmol of 5'-end-labeled 32P-RNA (approximately5 x 104 c.p.m.) and 10 mM Tris-HCl, pH 7.4. Reactions were incubated for 5 min at 37degreesC unless otherwise indicated, placed in liquid nitrogen, and then at 80-90degreesC to inactivate the enzyme. Five microliters of loading dye (9 M urea, 0.2% xylene cyanol, 0.2% bromophenol blue) were added to the reaction sample, and 5 mul of the reaction mixtures were subjected to electrophoresis in 8% or 12% polyacrylamide, 7 M urea gel depending on the type of experiments. Gels were then dried and exposed to PhosphorImager screen (Cyclone PhosphorImager). To determine if the native enzyme was N-glycosylated, 100 U of N-glycosidase F (Roche Diagnostics, Germany) was incubated with 3.0 ml of post heparin-Sepharose samples overnight at 30degreesC before subjecting the samples to gel filtration analysis. The 0.5-ml fractions were collected and analyzed for the presence of endoribonuclease activity as described above. To determine if the native enzyme was composed of multi-subunits linked by disulfide bonds, 3.0 ml of post heparin-Sepharose samples was incubated with 250 mM DTT for 1 h at 4degreesC before subjecting the samples to gel filtration analysis followed by endoribonuclease assay. For mapping RNA cleavage sites, RNase T1 digestion and alkaline hydrolysis of 5'-radiolabeled RNA were performed as described previously (30) and samples were separated on a 12% polyacrylamide/7 M urea gel.
###end p 12
###begin title 13
Western blot analysis
###end title 13
###begin p 14
Protein samples were separated in a 12.5% polyacrylamide/SDS Lammeli gel system, transferred to a nitrocellulose membrane and incubated against APE1 monoclonal antibody (Affinity Bioreagents, Colorado) or RNase A polyclonal antibody (GeneTex Inc, San Antonio). For re-use, some blots were stripped by incubating at 50-55degreesC with gentle shaking in 63 mM Tris. pH 6.7, 2% SDS, 100 mM beta-mercaptoethanol. Full-range rainbow marker (GE Healthcare, Quebec) was used to identify size of bands. Sizes of the marker proteins in kDa are: 250, 160, 105, 75, 50, 35, 30, 25, 15 and 10.
###end p 14
###begin title 15
Immunodepletion of the native 35-kDa purified endoribonuclease
###end title 15
###begin p 16
PIERCE Seize X Protein A Immunoprecipitation kit (MJS BioLynx Inc, Ontario) was used to assess whether the endoribonuclease activity from the native 35-kDa purified enzyme was attributed to APE1. Preparation of the spin cup containing Protein A cross-linked to 50 mug of APE1 or syntaxin18 monoclonal antibody was performed according to the manufacturer's instruction. After equilibrating with the binding/wash buffer (8 mM sodium phosphate, 2 mM potassium phosphate, 140 mM NaCl, 10 mM KCl, pH 7.4), 400 mul of gel filtration purified 35-kDa native enzyme were loaded and incubated with gentle rocking for 2 h at 4degreesC. Spin cups were spun at 3000 r.p.m. for 30 s and the flow through buffer was used for analysis. Four hundred microliters of binding/wash buffer was added to the mix, and the spin cups were spun again. This was repeated a total of three times and washed buffer from each spin kept for analysis. Finally, bound proteins were eluted with 3 x 200 mul elution buffer (primary amine solution, pH 2.8) followed by immediate neutralization with equal volume of Tris-Cl, pH 9.5.
###end p 16
###begin title 17
Purification of recombinant proteins
###end title 17
###begin p 18
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 579 580 579 580 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 675 677 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 540 545 <span type="species:ncbi:9606">human</span>
The plasmid pET15b-hAPE1 containing human APE1 cDNA was used to express the recombinant APE1 in BL21(DE3) cells. The His-tagged APE1 was first purified using Ni-NTA column chromatography as described (32). Following removal of the His-tag with thrombin, the recombinant protein was further purified by Superdex HiPrep FPLC (GE Healthcare). Just prior to use, the recombinant protein was dialyzed for 5 h against 10 mM Tris-HCl, pH 7.4, 2 mM DTT, 2 mM magnesium acetate, and 50 mM potassium acetate, with two buffer changes. The recombinant human mutant APE1, H309N and E96A, and l-3-hydroxyacyl-CoA dehydrogenase (HADHSC) were purified in the same manner as described above (33). The recombinant annexin III was purchased from GenWay Biotech (San Diego).
###end p 18
###begin title 19
Cell culture and siRNA transfection
###end title 19
###begin p 20
###xml 147 148 141 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 200 201 182 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 964 966 946 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 99 105 <span type="species:ncbi:9913">bovine</span>
Human cervical cancer cell line HeLa (ATCC) was cultured in MEM medium supplemented with 10% fetal bovine serum (Invitrogen) at 37degreesC in 5% CO2. The day before transfection, approximately1.0 x 105 cells were plated per well in 6-well plates. Transient transfection of 60 nM siRNAs was carried out using Lipofectamine 2000 reagent (Invitrogen) as according to the manufacturer's instructions. The double-stranded Dicer substrate RNAi directed against APE1 mRNA was chemically synthesized (IDT Inc.). The sense and antisense sequences were: r(GUCUGGUACGACUGGAGUACCGG)dCA and r(UGCCGGUACUCCAGUCGUACCAGACCU). As control, the DS Scrambled Negative (IDT Inc.) was used. The sense and antisense sequences of DS Scrambled Negative were: r(CUUCCUCUCUUUCUCUCCCUUGU)dGA and r(UCACAAGGGAGAGAAAGAGAGGAAGGA). Cells from duplicate wells in each experiment were subjected to either total RNA extraction as described below or to cell lysate isolation as previously described (33).
###end p 20
###begin title 21
Total RNA extraction and quantitative reverse transcription-PCR
###end title 21
###begin p 22
###xml 126 129 126 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 638 641 634 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 697 700 693 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 1417 1418 1389 1390 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1455 1458 1427 1430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 1527 1528 1496 1497 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1562 1575 1531 1536 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#916;&#916;CT</sup>
###xml 1584 1586 1545 1547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
Total RNA was extracted from cells using TRIzol reagent (Invitrogen) as according to the manufacturer's instructions. APE1, c-myc and beta-actin mRNA levels were examined by quantitative real-time reverse transcription-PCR (qRT-PCR). The first strand cDNA synthesis was performed using QuantiTect RT kit (Qiagen) on 1 mug of total RNA, and the qRT-PCR was performed using iQ SYBR Green Supermix (Bio-Rad) on an iQ5 Multicolor Real-Time PCR Detection System (Bio-Rad). The PCR primers synthesized by IDT Inc. were: APE1 forward primer, 5'-TGG AAT GTG GAT GGG CTT CGA GCC-3' and APE1 reverse primer, 5'-AAG GAG CTG ACC AGT ATT GAT GA-3'; c-myc forward primer, 5'-ACG AAA CTT TGC CCA TAG CA-3' and c-myc reverse primer, 5' GCA AGG AGA GCC TTT CAG AG-3'; beta-actin forward primer, 5'-TTG CCG ACA GGA TGC AGA AGG A-3' and beta-actin reverse primer, 5'-AGG TGG ACA GCG AGG CCA GGA T-3'. The cycling protocol consisted of 95degreesC for 3 min and 40 cycles of denaturation at 95degreesC for 10 s, annealing at 52degreesC for 30 s. To confirm amplification specificity, we performed a melting curve analysis at the end of each cycling. Each sample was run in triplicate. The data were analyzed using iQ5 optical system software. Serial dilutions were carried out for each total RNA sample and reverse-transcribed under the above-mentioned conditions for each primer set to ensure amplification with efficiencies near 100%. CT values for target genes (APE1 and c-myc) and reference gene (beta-actin) were then used in the comparative CT method or commonly known as the 2-DeltaDeltaCT method (34) to determine the expression level of target gene in APE1-knockdown samples relative to the DS Scrambled Negative-treated sample.
###end p 22
###begin title 23
Statistical analysis
###end title 23
###begin p 24
###xml 36 37 36 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 61 69 61 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 119 127 119 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F9">Figure 9</xref>
###xml 191 200 191 200 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1.</label>
###xml 294 295 294 295 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 410 412 410 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 428 431 428 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 707 708 701 702 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 785 786 779 780 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 200 991 200 985 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="25">Purification and identification of proteins that co-purified with endoribonuclease activity. (<bold>A</bold>) Autoradiograph of an endoribonuclease assay in gel filtration fractions (elution volume 20&#8211;76) using 350 fmol 5&#8242; <sup>32</sup>P-labeled CRD c-<italic>myc</italic> RNA as substrate. The endoribonuclease assay was performed for 5 min at 37&#176;C under the standard condition as described in the &#8216;Materials and Methods&#8217; section. Filled arrow indicates undigested substrate RNA and unfilled arrow indicates endonucleolytic decay products. (<bold>B</bold>) Silver-stained SDS&#8211;PAGE gel of pooled samples from gel filtration in (A). (<bold>C</bold>) Coomasie blue-stained SDS&#8211;PAGE gel of pooled samples from three separate gel filtration columns. Arrows indicate protein bands that were excised and subjected to LC-MS/MS protein identification analysis.</p>
###xml 200 991 200 985 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="25">Purification and identification of proteins that co-purified with endoribonuclease activity. (<bold>A</bold>) Autoradiograph of an endoribonuclease assay in gel filtration fractions (elution volume 20&#8211;76) using 350 fmol 5&#8242; <sup>32</sup>P-labeled CRD c-<italic>myc</italic> RNA as substrate. The endoribonuclease assay was performed for 5 min at 37&#176;C under the standard condition as described in the &#8216;Materials and Methods&#8217; section. Filled arrow indicates undigested substrate RNA and unfilled arrow indicates endonucleolytic decay products. (<bold>B</bold>) Silver-stained SDS&#8211;PAGE gel of pooled samples from gel filtration in (A). (<bold>C</bold>) Coomasie blue-stained SDS&#8211;PAGE gel of pooled samples from three separate gel filtration columns. Arrows indicate protein bands that were excised and subjected to LC-MS/MS protein identification analysis.</p></caption>
###xml 991 991 985 985 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp275f1"/>
###xml 191 991 191 985 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F1" position="float"><label>Figure 1.</label><caption><p textid="25">Purification and identification of proteins that co-purified with endoribonuclease activity. (<bold>A</bold>) Autoradiograph of an endoribonuclease assay in gel filtration fractions (elution volume 20&#8211;76) using 350 fmol 5&#8242; <sup>32</sup>P-labeled CRD c-<italic>myc</italic> RNA as substrate. The endoribonuclease assay was performed for 5 min at 37&#176;C under the standard condition as described in the &#8216;Materials and Methods&#8217; section. Filled arrow indicates undigested substrate RNA and unfilled arrow indicates endonucleolytic decay products. (<bold>B</bold>) Silver-stained SDS&#8211;PAGE gel of pooled samples from gel filtration in (A). (<bold>C</bold>) Coomasie blue-stained SDS&#8211;PAGE gel of pooled samples from three separate gel filtration columns. Arrows indicate protein bands that were excised and subjected to LC-MS/MS protein identification analysis.</p></caption><graphic xlink:href="gkp275f1"/></fig>
###xml 991 1000 985 994 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2.</label>
###xml 1098 1099 1092 1093 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1149 1152 1143 1146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 1609 1611 1603 1605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 1612 1614 1606 1608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 2228 2229 2222 2223 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2256 2259 2250 2253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 1000 2332 994 2326 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="26">Mapping the cleavage sites generated by the purified 17-kDa and 35-kDa native endoribonucleases. (<bold>A</bold>) Three hundred and fifty femtomole 5&#8242; -labeled c-<italic>myc</italic> CRD RNA were subjected to post-heparin-Sepharose purified enzyme (lanes 3 and 9), 30&#8211;40-kDa fraction purified enzyme (lanes 4&#8211;6 and 12 and 13) and 10&#8211;20-kDa fraction purified enzyme (lanes 10 and 11) from gel filtration column under the standard endoribonuclease assay. The radiolabeled RNA was also subjected to alkaline hydrolysis (lanes 7 and 14), bovine pancreatic RNase A (1 U) (lane 8), and RNase T1 digestion (1 U) (lane 1) as described previously (<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>). Samples were run on a 12% polyacrylamide/7 M urea gel. The amount of 30&#8211;40-kDa fraction purified enzyme used were 0.75 U (lane 4), 0.6 U (lane 5), 0.4 U (lane 6), 0.2 U (lane 12) and 0.1 U (lane 13). The amount of 10&#8211;20-kDa fraction purified enzyme used were 3 U (lane 10) and 1 U (lane 11). Asterisks indicate the 1751UA dinucleotide preferentially cleaved by the 30&#8211;40-kDa fraction enzyme. Arrows on the left indicate guanosine cleavage sites generated by RNase T1 and the numbers indicate position of nucleotide sequence. Numbers on the right indicate the cleavage sites generated by the endoribonucleases. (<bold>B</bold>) Secondary structure of c-<italic>myc</italic> CRD RNA and the cleavage sites generated by the 35-kDa endoribonuclease.</p>
###xml 1000 2332 994 2326 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="26">Mapping the cleavage sites generated by the purified 17-kDa and 35-kDa native endoribonucleases. (<bold>A</bold>) Three hundred and fifty femtomole 5&#8242; -labeled c-<italic>myc</italic> CRD RNA were subjected to post-heparin-Sepharose purified enzyme (lanes 3 and 9), 30&#8211;40-kDa fraction purified enzyme (lanes 4&#8211;6 and 12 and 13) and 10&#8211;20-kDa fraction purified enzyme (lanes 10 and 11) from gel filtration column under the standard endoribonuclease assay. The radiolabeled RNA was also subjected to alkaline hydrolysis (lanes 7 and 14), bovine pancreatic RNase A (1 U) (lane 8), and RNase T1 digestion (1 U) (lane 1) as described previously (<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>). Samples were run on a 12% polyacrylamide/7 M urea gel. The amount of 30&#8211;40-kDa fraction purified enzyme used were 0.75 U (lane 4), 0.6 U (lane 5), 0.4 U (lane 6), 0.2 U (lane 12) and 0.1 U (lane 13). The amount of 10&#8211;20-kDa fraction purified enzyme used were 3 U (lane 10) and 1 U (lane 11). Asterisks indicate the 1751UA dinucleotide preferentially cleaved by the 30&#8211;40-kDa fraction enzyme. Arrows on the left indicate guanosine cleavage sites generated by RNase T1 and the numbers indicate position of nucleotide sequence. Numbers on the right indicate the cleavage sites generated by the endoribonucleases. (<bold>B</bold>) Secondary structure of c-<italic>myc</italic> CRD RNA and the cleavage sites generated by the 35-kDa endoribonuclease.</p></caption>
###xml 2332 2332 2326 2326 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp275f2"/>
###xml 991 2332 985 2326 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F2" position="float"><label>Figure 2.</label><caption><p textid="26">Mapping the cleavage sites generated by the purified 17-kDa and 35-kDa native endoribonucleases. (<bold>A</bold>) Three hundred and fifty femtomole 5&#8242; -labeled c-<italic>myc</italic> CRD RNA were subjected to post-heparin-Sepharose purified enzyme (lanes 3 and 9), 30&#8211;40-kDa fraction purified enzyme (lanes 4&#8211;6 and 12 and 13) and 10&#8211;20-kDa fraction purified enzyme (lanes 10 and 11) from gel filtration column under the standard endoribonuclease assay. The radiolabeled RNA was also subjected to alkaline hydrolysis (lanes 7 and 14), bovine pancreatic RNase A (1 U) (lane 8), and RNase T1 digestion (1 U) (lane 1) as described previously (<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>). Samples were run on a 12% polyacrylamide/7 M urea gel. The amount of 30&#8211;40-kDa fraction purified enzyme used were 0.75 U (lane 4), 0.6 U (lane 5), 0.4 U (lane 6), 0.2 U (lane 12) and 0.1 U (lane 13). The amount of 10&#8211;20-kDa fraction purified enzyme used were 3 U (lane 10) and 1 U (lane 11). Asterisks indicate the 1751UA dinucleotide preferentially cleaved by the 30&#8211;40-kDa fraction enzyme. Arrows on the left indicate guanosine cleavage sites generated by RNase T1 and the numbers indicate position of nucleotide sequence. Numbers on the right indicate the cleavage sites generated by the endoribonucleases. (<bold>B</bold>) Secondary structure of c-<italic>myc</italic> CRD RNA and the cleavage sites generated by the 35-kDa endoribonuclease.</p></caption><graphic xlink:href="gkp275f2"/></fig>
###xml 2332 2341 2326 2335 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3.</label>
###xml 2341 2610 2335 2603 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="27">Presence of RNase1 and APE1 in partially purified native enzyme. Western blot analysis of pooled samples from gel filtration (lanes 3&#8211;8) as detected by RNase A (upper panel) or APE1 (lower panel) antibody. Lane 1 contains 5 &#956;g of recombinant bovine pancreatic RNase A.</p>
###xml 2341 2610 2335 2603 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="27">Presence of RNase1 and APE1 in partially purified native enzyme. Western blot analysis of pooled samples from gel filtration (lanes 3&#8211;8) as detected by RNase A (upper panel) or APE1 (lower panel) antibody. Lane 1 contains 5 &#956;g of recombinant bovine pancreatic RNase A.</p></caption>
###xml 2610 2610 2603 2603 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp275f3"/>
###xml 2332 2610 2326 2603 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F3" position="float"><label>Figure 3.</label><caption><p textid="27">Presence of RNase1 and APE1 in partially purified native enzyme. Western blot analysis of pooled samples from gel filtration (lanes 3&#8211;8) as detected by RNase A (upper panel) or APE1 (lower panel) antibody. Lane 1 contains 5 &#956;g of recombinant bovine pancreatic RNase A.</p></caption><graphic xlink:href="gkp275f3"/></fig>
###xml 2610 2619 2603 2612 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4.</label>
###xml 2712 2713 2705 2706 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 2972 2975 2965 2968 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 3386 3389 3379 3382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 3467 3468 3460 3461 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 3705 3706 3697 3698 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 4061 4064 4053 4056 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 2619 4121 2612 4113 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="28">Immuno-depletion of the 35-kDa endoribonuclease activity using APE1 or syntaxin18 antibody. (<bold>A</bold>) Partially purified 35-kDa native enzyme was subjected to Seize X Protein A spin column which has been cross-linked with anti-APE1 antibody. Four microliters of washed (lanes 6 and 7) and eluted samples (lanes 8&#8211;10) were tested against 350 fmol 5&#8242;-labeled c-<italic>myc</italic> CRD RNA as described in &#8216;Materials and Methods&#8217; section. Lane 1 contains the RNA only without any treatment with proteins. Lanes 2 and 3 contain 2 U and 3 U, respectively, of partially purified native enzyme from heparin-Sepharose column. Lanes 4 and 5 are 0.75 U and 1 U, respectively, of pre-loaded partially purified 30&#8211;40-kDa fraction native enzyme from gel filtration. Filled arrow indicates the intact c-<italic>myc</italic> CRD RNA and the decay products are shown with a bracket and unfilled arrow. (<bold>B</bold>) Western blot analysis of samples from (A) as detected using anti-APE1 antibody. Lane 1 contains 0.5 &#956;g recombinant APE1 and lane 2 has the partially purified 30&#8211;40-kDa fraction native enzyme. FT is flow-through from the spin column. (<bold>C</bold>) As in (A), partially purified 35-kDa native enzyme was subjected to spin column which has been cross-linked with anti-syntaxin18 antibody. Lane 1 contains 2 U of partially purified native enzyme from heparin-Sepharose column. Four microliters of flow through (lane 2), washed (lane 3) and eluted samples (lanes 4 and 5) were tested against 5&#8242;-labeled c-<italic>myc</italic> CRD RNA as described in &#8216;Materials and methods&#8217; section.</p>
###xml 2619 4121 2612 4113 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="28">Immuno-depletion of the 35-kDa endoribonuclease activity using APE1 or syntaxin18 antibody. (<bold>A</bold>) Partially purified 35-kDa native enzyme was subjected to Seize X Protein A spin column which has been cross-linked with anti-APE1 antibody. Four microliters of washed (lanes 6 and 7) and eluted samples (lanes 8&#8211;10) were tested against 350 fmol 5&#8242;-labeled c-<italic>myc</italic> CRD RNA as described in &#8216;Materials and Methods&#8217; section. Lane 1 contains the RNA only without any treatment with proteins. Lanes 2 and 3 contain 2 U and 3 U, respectively, of partially purified native enzyme from heparin-Sepharose column. Lanes 4 and 5 are 0.75 U and 1 U, respectively, of pre-loaded partially purified 30&#8211;40-kDa fraction native enzyme from gel filtration. Filled arrow indicates the intact c-<italic>myc</italic> CRD RNA and the decay products are shown with a bracket and unfilled arrow. (<bold>B</bold>) Western blot analysis of samples from (A) as detected using anti-APE1 antibody. Lane 1 contains 0.5 &#956;g recombinant APE1 and lane 2 has the partially purified 30&#8211;40-kDa fraction native enzyme. FT is flow-through from the spin column. (<bold>C</bold>) As in (A), partially purified 35-kDa native enzyme was subjected to spin column which has been cross-linked with anti-syntaxin18 antibody. Lane 1 contains 2 U of partially purified native enzyme from heparin-Sepharose column. Four microliters of flow through (lane 2), washed (lane 3) and eluted samples (lanes 4 and 5) were tested against 5&#8242;-labeled c-<italic>myc</italic> CRD RNA as described in &#8216;Materials and methods&#8217; section.</p></caption>
###xml 4121 4121 4113 4113 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp275f4"/>
###xml 2610 4121 2603 4113 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F4" position="float"><label>Figure 4.</label><caption><p textid="28">Immuno-depletion of the 35-kDa endoribonuclease activity using APE1 or syntaxin18 antibody. (<bold>A</bold>) Partially purified 35-kDa native enzyme was subjected to Seize X Protein A spin column which has been cross-linked with anti-APE1 antibody. Four microliters of washed (lanes 6 and 7) and eluted samples (lanes 8&#8211;10) were tested against 350 fmol 5&#8242;-labeled c-<italic>myc</italic> CRD RNA as described in &#8216;Materials and Methods&#8217; section. Lane 1 contains the RNA only without any treatment with proteins. Lanes 2 and 3 contain 2 U and 3 U, respectively, of partially purified native enzyme from heparin-Sepharose column. Lanes 4 and 5 are 0.75 U and 1 U, respectively, of pre-loaded partially purified 30&#8211;40-kDa fraction native enzyme from gel filtration. Filled arrow indicates the intact c-<italic>myc</italic> CRD RNA and the decay products are shown with a bracket and unfilled arrow. (<bold>B</bold>) Western blot analysis of samples from (A) as detected using anti-APE1 antibody. Lane 1 contains 0.5 &#956;g recombinant APE1 and lane 2 has the partially purified 30&#8211;40-kDa fraction native enzyme. FT is flow-through from the spin column. (<bold>C</bold>) As in (A), partially purified 35-kDa native enzyme was subjected to spin column which has been cross-linked with anti-syntaxin18 antibody. Lane 1 contains 2 U of partially purified native enzyme from heparin-Sepharose column. Four microliters of flow through (lane 2), washed (lane 3) and eluted samples (lanes 4 and 5) were tested against 5&#8242;-labeled c-<italic>myc</italic> CRD RNA as described in &#8216;Materials and methods&#8217; section.</p></caption><graphic xlink:href="gkp275f4"/></fig>
###xml 4121 4130 4113 4122 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5.</label>
###xml 4181 4184 4173 4176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 4195 4196 4187 4188 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 4539 4540 4528 4529 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 4577 4580 4566 4569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 4852 4855 4840 4843 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 4130 5306 4122 5293 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="29">Endoribonuclease activity of recombinant APE1 on c-<italic>myc</italic> CRD RNA. (<bold>A</bold>) Left panel, Coomasie blue-stained SDS&#8211;PAGE gel of recombinant human APE1 at 5 &#956;g (lane 2) and 1 &#956;g (lane 3). Lane 1 is molecular weight marker. Right panel, western blot analysis of 3 &#956;g of recombinant human APE1 generated by us (lane 1) or in Dr. Hickson's laboratory (lane 2), as detected by specific monoclonal antibody against APE1. (<bold>B</bold>) Left panel, 350 fmol 5&#8242; -labeled c-<italic>myc</italic> CRD RNA were treated with 0.1 U of the partially purified 35-kDa native enzyme for 5 min (lanes 2 and 3), or with 0.05 &#956;g of purified recombinant human APE1 generated in Dr. Hickson's laboratory (lane 4). Lane 1 had no protein added. Right panel, 350 fmol 5&#8242; -labeled c-<italic>myc</italic> CRD RNA were treated with 0.1 &#956;g of purified and renatured recombinant human APE1 for 5 min (lane 2), 10 min (lane 3) and 20 min (lane 4), or with 0.1 U of the partially purified 35-kDa native enzyme for 5 min (lane 5), 10 min (lane 6) and 20 min (lane 7) under the standard endoribonuclease assay. Lane 1 had no protein added. Samples were run on 8% polyarylamide/7 M urea gel. Numbers on the right indicate cleavage sites generated by the enzymes.</p>
###xml 4130 5306 4122 5293 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="29">Endoribonuclease activity of recombinant APE1 on c-<italic>myc</italic> CRD RNA. (<bold>A</bold>) Left panel, Coomasie blue-stained SDS&#8211;PAGE gel of recombinant human APE1 at 5 &#956;g (lane 2) and 1 &#956;g (lane 3). Lane 1 is molecular weight marker. Right panel, western blot analysis of 3 &#956;g of recombinant human APE1 generated by us (lane 1) or in Dr. Hickson's laboratory (lane 2), as detected by specific monoclonal antibody against APE1. (<bold>B</bold>) Left panel, 350 fmol 5&#8242; -labeled c-<italic>myc</italic> CRD RNA were treated with 0.1 U of the partially purified 35-kDa native enzyme for 5 min (lanes 2 and 3), or with 0.05 &#956;g of purified recombinant human APE1 generated in Dr. Hickson's laboratory (lane 4). Lane 1 had no protein added. Right panel, 350 fmol 5&#8242; -labeled c-<italic>myc</italic> CRD RNA were treated with 0.1 &#956;g of purified and renatured recombinant human APE1 for 5 min (lane 2), 10 min (lane 3) and 20 min (lane 4), or with 0.1 U of the partially purified 35-kDa native enzyme for 5 min (lane 5), 10 min (lane 6) and 20 min (lane 7) under the standard endoribonuclease assay. Lane 1 had no protein added. Samples were run on 8% polyarylamide/7 M urea gel. Numbers on the right indicate cleavage sites generated by the enzymes.</p></caption>
###xml 5306 5306 5293 5293 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp275f5"/>
###xml 4121 5306 4113 5293 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F5" position="float"><label>Figure 5.</label><caption><p textid="29">Endoribonuclease activity of recombinant APE1 on c-<italic>myc</italic> CRD RNA. (<bold>A</bold>) Left panel, Coomasie blue-stained SDS&#8211;PAGE gel of recombinant human APE1 at 5 &#956;g (lane 2) and 1 &#956;g (lane 3). Lane 1 is molecular weight marker. Right panel, western blot analysis of 3 &#956;g of recombinant human APE1 generated by us (lane 1) or in Dr. Hickson's laboratory (lane 2), as detected by specific monoclonal antibody against APE1. (<bold>B</bold>) Left panel, 350 fmol 5&#8242; -labeled c-<italic>myc</italic> CRD RNA were treated with 0.1 U of the partially purified 35-kDa native enzyme for 5 min (lanes 2 and 3), or with 0.05 &#956;g of purified recombinant human APE1 generated in Dr. Hickson's laboratory (lane 4). Lane 1 had no protein added. Right panel, 350 fmol 5&#8242; -labeled c-<italic>myc</italic> CRD RNA were treated with 0.1 &#956;g of purified and renatured recombinant human APE1 for 5 min (lane 2), 10 min (lane 3) and 20 min (lane 4), or with 0.1 U of the partially purified 35-kDa native enzyme for 5 min (lane 5), 10 min (lane 6) and 20 min (lane 7) under the standard endoribonuclease assay. Lane 1 had no protein added. Samples were run on 8% polyarylamide/7 M urea gel. Numbers on the right indicate cleavage sites generated by the enzymes.</p></caption><graphic xlink:href="gkp275f5"/></fig>
###xml 5306 5315 5293 5302 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6.</label>
###xml 5375 5376 5362 5363 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 5413 5416 5400 5403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 5739 5742 5719 5722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 6026 6027 6006 6007 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 6042 6045 6022 6025 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 5315 6262 5302 6236 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="30">Endoribonuclease activity of recombinant APE1 polypeptide. (<bold>A</bold>) Left panel, 350 fmol 5&#8242; -labeled c-<italic>myc</italic> CRD RNA were treated with the purified and renatured wild-type APE1 (lanes 2 and 9), H309N (lanes 3&#8211;5) or E96A (lanes 6&#8211;8) mutant APE1 for 5 min at 37&#176;C at the amount indicated under the standard endoribonuclease assay containing 20 &#956;l reaction. Lanes 1 and 10, no protein added. Right panel, 350 fmol 5&#8242;-labeled c-<italic>myc</italic> CRD RNA were treated with the purified and renatured wild-type recombinant APE1 (lane 2) or N-terminus truncated APE1, ND42 (lane 3). Lane 1, no protein added. Samples were run on 8% polyarylamide/7 M urea gel. Numbers on the right indicate cleavage sites generated by the enzymes. (<bold>B</bold>) 5&#8242;-labeled c-<italic>myc</italic> CRD RNA were treated with purified recombinant human APE1 (lanes 2 and 3), HADHSC (lanes 4 and 5) or annexin3 (lanes 6 and 7) for 5 min at 37&#176;C at the amount indicated under the standard endoribonuclease assay.</p>
###xml 5315 6262 5302 6236 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="30">Endoribonuclease activity of recombinant APE1 polypeptide. (<bold>A</bold>) Left panel, 350 fmol 5&#8242; -labeled c-<italic>myc</italic> CRD RNA were treated with the purified and renatured wild-type APE1 (lanes 2 and 9), H309N (lanes 3&#8211;5) or E96A (lanes 6&#8211;8) mutant APE1 for 5 min at 37&#176;C at the amount indicated under the standard endoribonuclease assay containing 20 &#956;l reaction. Lanes 1 and 10, no protein added. Right panel, 350 fmol 5&#8242;-labeled c-<italic>myc</italic> CRD RNA were treated with the purified and renatured wild-type recombinant APE1 (lane 2) or N-terminus truncated APE1, ND42 (lane 3). Lane 1, no protein added. Samples were run on 8% polyarylamide/7 M urea gel. Numbers on the right indicate cleavage sites generated by the enzymes. (<bold>B</bold>) 5&#8242;-labeled c-<italic>myc</italic> CRD RNA were treated with purified recombinant human APE1 (lanes 2 and 3), HADHSC (lanes 4 and 5) or annexin3 (lanes 6 and 7) for 5 min at 37&#176;C at the amount indicated under the standard endoribonuclease assay.</p></caption>
###xml 6262 6262 6236 6236 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp275f6"/>
###xml 5306 6262 5293 6236 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F6" position="float"><label>Figure 6.</label><caption><p textid="30">Endoribonuclease activity of recombinant APE1 polypeptide. (<bold>A</bold>) Left panel, 350 fmol 5&#8242; -labeled c-<italic>myc</italic> CRD RNA were treated with the purified and renatured wild-type APE1 (lanes 2 and 9), H309N (lanes 3&#8211;5) or E96A (lanes 6&#8211;8) mutant APE1 for 5 min at 37&#176;C at the amount indicated under the standard endoribonuclease assay containing 20 &#956;l reaction. Lanes 1 and 10, no protein added. Right panel, 350 fmol 5&#8242;-labeled c-<italic>myc</italic> CRD RNA were treated with the purified and renatured wild-type recombinant APE1 (lane 2) or N-terminus truncated APE1, ND42 (lane 3). Lane 1, no protein added. Samples were run on 8% polyarylamide/7 M urea gel. Numbers on the right indicate cleavage sites generated by the enzymes. (<bold>B</bold>) 5&#8242;-labeled c-<italic>myc</italic> CRD RNA were treated with purified recombinant human APE1 (lanes 2 and 3), HADHSC (lanes 4 and 5) or annexin3 (lanes 6 and 7) for 5 min at 37&#176;C at the amount indicated under the standard endoribonuclease assay.</p></caption><graphic xlink:href="gkp275f6"/></fig>
###xml 6262 6271 6236 6245 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7.</label>
###xml 6302 6305 6276 6279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 6372 6374 6346 6348 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 6416 6418 6386 6388 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 6431 6432 6397 6398 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 6976 6977 6941 6942 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 7042 7045 7007 7010 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 6271 7538 6245 7502 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="31">APE1 is an endoribonuclease. c-<italic>myc</italic> CRD RNA corresponding to nts 1730&#8211;1766 was either 5&#8242;-labeled with <sup>32</sup>P-&#947;-ATP (A) or uniformly labeled with <sup>32</sup>P-&#945;-UTP (<bold>B</bold>) before subjecting to 0.1 &#956;g purified recombinant human APE1 for 2 min (lane 2) or 5 min (lane 3) under the standard endoribonuclease assay. Samples were run on 8% polyarylamide/7 M urea gel. The secondary structure of RNA is on the right of each figure and arrows indicate the cleavage sites generated by APE1. Asterisks on the structure in (B) indicate radiolabeled uridine. Schematic RNA secondary structures on the right represent 5&#8242;fragment of cleavage products while those on the left in (B) represent 3&#8242;fragment of cleavage products. (<bold>C</bold>) 5&#8242;-labeled oligonucleotide corresponding to nts 1742&#8211;1757 of c-<italic>myc</italic> CRD was treated for 5 min with increasing concentrations (0.08&#8211;0.8 &#956;g) of recombinant APE1 (lanes 3&#8211;9) or with 2 U partially purified native APE1 from heparin sepharose column (lane 2). Samples were run on 12% polyarylamide/7 M urea gel. The secondary structure of the oligo is on the right panel and the arrow indicates the RNA cleavage site generated by APE1. Schematic secondary structures on the right represent the full-length oligo (top) or 5&#8242;fragment of the cleavage product (bottom).</p>
###xml 6271 7538 6245 7502 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="31">APE1 is an endoribonuclease. c-<italic>myc</italic> CRD RNA corresponding to nts 1730&#8211;1766 was either 5&#8242;-labeled with <sup>32</sup>P-&#947;-ATP (A) or uniformly labeled with <sup>32</sup>P-&#945;-UTP (<bold>B</bold>) before subjecting to 0.1 &#956;g purified recombinant human APE1 for 2 min (lane 2) or 5 min (lane 3) under the standard endoribonuclease assay. Samples were run on 8% polyarylamide/7 M urea gel. The secondary structure of RNA is on the right of each figure and arrows indicate the cleavage sites generated by APE1. Asterisks on the structure in (B) indicate radiolabeled uridine. Schematic RNA secondary structures on the right represent 5&#8242;fragment of cleavage products while those on the left in (B) represent 3&#8242;fragment of cleavage products. (<bold>C</bold>) 5&#8242;-labeled oligonucleotide corresponding to nts 1742&#8211;1757 of c-<italic>myc</italic> CRD was treated for 5 min with increasing concentrations (0.08&#8211;0.8 &#956;g) of recombinant APE1 (lanes 3&#8211;9) or with 2 U partially purified native APE1 from heparin sepharose column (lane 2). Samples were run on 12% polyarylamide/7 M urea gel. The secondary structure of the oligo is on the right panel and the arrow indicates the RNA cleavage site generated by APE1. Schematic secondary structures on the right represent the full-length oligo (top) or 5&#8242;fragment of the cleavage product (bottom).</p></caption>
###xml 7538 7538 7502 7502 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp275f7"/>
###xml 6262 7538 6236 7502 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F7" position="float"><label>Figure 7.</label><caption><p textid="31">APE1 is an endoribonuclease. c-<italic>myc</italic> CRD RNA corresponding to nts 1730&#8211;1766 was either 5&#8242;-labeled with <sup>32</sup>P-&#947;-ATP (A) or uniformly labeled with <sup>32</sup>P-&#945;-UTP (<bold>B</bold>) before subjecting to 0.1 &#956;g purified recombinant human APE1 for 2 min (lane 2) or 5 min (lane 3) under the standard endoribonuclease assay. Samples were run on 8% polyarylamide/7 M urea gel. The secondary structure of RNA is on the right of each figure and arrows indicate the cleavage sites generated by APE1. Asterisks on the structure in (B) indicate radiolabeled uridine. Schematic RNA secondary structures on the right represent 5&#8242;fragment of cleavage products while those on the left in (B) represent 3&#8242;fragment of cleavage products. (<bold>C</bold>) 5&#8242;-labeled oligonucleotide corresponding to nts 1742&#8211;1757 of c-<italic>myc</italic> CRD was treated for 5 min with increasing concentrations (0.08&#8211;0.8 &#956;g) of recombinant APE1 (lanes 3&#8211;9) or with 2 U partially purified native APE1 from heparin sepharose column (lane 2). Samples were run on 12% polyarylamide/7 M urea gel. The secondary structure of the oligo is on the right panel and the arrow indicates the RNA cleavage site generated by APE1. Schematic secondary structures on the right represent the full-length oligo (top) or 5&#8242;fragment of the cleavage product (bottom).</p></caption><graphic xlink:href="gkp275f7"/></fig>
###xml 7538 7547 7502 7511 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8.</label>
###xml 7574 7577 7538 7541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 7605 7606 7569 7570 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 7767 7768 7726 7727 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 7954 7955 7908 7909 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 8056 8057 8010 8011 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 8184 8185 8136 8137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 8338 8341 8287 8290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 8364 8367 8313 8316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 7547 8463 7511 8409 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="32">APE1 knockdown increases c-<italic>myc</italic> mRNA level in HeLa cells. (<bold>A</bold>) Western blot analysis of APE1 and &#946;-actin protein levels in HeLa cells at 24 and 48 h after transfection with 20 &#956;M Control-dsRNAi or 20 &#956;M APE1-dsRNAi. (<bold>B</bold>) APE1 and &#946;-actin mRNA levels in HeLa cells transfected with 20 &#956;M APE1-dsRNAi or 20 &#956;M Control-dsRNAi for 24 and 48 h were analyzed by quantitative real-time RT-PCR (top panel). C<sub>T</sub> values obtained in triplicates from separate transfection experiments were used in the comparative C<sub>T</sub> method calculation as described in &#8216;Materials and Methods&#8217; section. Data are mean &#177; SD of three independent experiments (*, <italic>P</italic> &lt; 0.05). The APE1/&#946;-actin mRNA ratios are presented as a percentage relative to Control-dsRNAi (top panel). The same RNA samples were analyzed for c-<italic>myc</italic> mRNA levels and the c-<italic>myc</italic>/&#946;-actin mRNA ratios are presented as a percentage relative to Control-dsRNAi (bottom panel).</p>
###xml 7547 8463 7511 8409 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="32">APE1 knockdown increases c-<italic>myc</italic> mRNA level in HeLa cells. (<bold>A</bold>) Western blot analysis of APE1 and &#946;-actin protein levels in HeLa cells at 24 and 48 h after transfection with 20 &#956;M Control-dsRNAi or 20 &#956;M APE1-dsRNAi. (<bold>B</bold>) APE1 and &#946;-actin mRNA levels in HeLa cells transfected with 20 &#956;M APE1-dsRNAi or 20 &#956;M Control-dsRNAi for 24 and 48 h were analyzed by quantitative real-time RT-PCR (top panel). C<sub>T</sub> values obtained in triplicates from separate transfection experiments were used in the comparative C<sub>T</sub> method calculation as described in &#8216;Materials and Methods&#8217; section. Data are mean &#177; SD of three independent experiments (*, <italic>P</italic> &lt; 0.05). The APE1/&#946;-actin mRNA ratios are presented as a percentage relative to Control-dsRNAi (top panel). The same RNA samples were analyzed for c-<italic>myc</italic> mRNA levels and the c-<italic>myc</italic>/&#946;-actin mRNA ratios are presented as a percentage relative to Control-dsRNAi (bottom panel).</p></caption>
###xml 8463 8463 8409 8409 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp275f8"/>
###xml 7538 8463 7502 8409 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F8" position="float"><label>Figure 8.</label><caption><p textid="32">APE1 knockdown increases c-<italic>myc</italic> mRNA level in HeLa cells. (<bold>A</bold>) Western blot analysis of APE1 and &#946;-actin protein levels in HeLa cells at 24 and 48 h after transfection with 20 &#956;M Control-dsRNAi or 20 &#956;M APE1-dsRNAi. (<bold>B</bold>) APE1 and &#946;-actin mRNA levels in HeLa cells transfected with 20 &#956;M APE1-dsRNAi or 20 &#956;M Control-dsRNAi for 24 and 48 h were analyzed by quantitative real-time RT-PCR (top panel). C<sub>T</sub> values obtained in triplicates from separate transfection experiments were used in the comparative C<sub>T</sub> method calculation as described in &#8216;Materials and Methods&#8217; section. Data are mean &#177; SD of three independent experiments (*, <italic>P</italic> &lt; 0.05). The APE1/&#946;-actin mRNA ratios are presented as a percentage relative to Control-dsRNAi (top panel). The same RNA samples were analyzed for c-<italic>myc</italic> mRNA levels and the c-<italic>myc</italic>/&#946;-actin mRNA ratios are presented as a percentage relative to Control-dsRNAi (bottom panel).</p></caption><graphic xlink:href="gkp275f8"/></fig>
###xml 8463 8472 8409 8418 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 9.</label>
###xml 8502 8505 8448 8451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 8575 8576 8521 8522 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 8875 8878 8817 8820 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 8943 8951 8882 8890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 8987 8990 8926 8929 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 9018 9021 8954 8957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 9316 9317 9247 9248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 8472 9326 8418 9257 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="33">Effect of APE1 knockdown on c-<italic>myc</italic> mRNA decay in HeLa cells. Twenty-four hours after plating at 1.0 &#215; 10<sup>5</sup> cells/well, cells were transfected with either 60 nM Control-dsRNAi or 60 nM APE1-dsRNAi. After a further 30 h incubation, cells were subjected to transcriptional inhibition by the addition of 200 &#181;M DRB. Total RNA was then extracted from cells after 20, 40 and 60 min of further incubation. c-<italic>myc</italic> and &#946;&#8211;actin mRNA levels were then quantified as described in <xref ref-type="fig" rid="F8">Figure 8</xref>. After normalizing the levels of c-<italic>myc</italic> mRNA to &#946;-actin mRNA, c-<italic>myc</italic>/&#946;-actin mRNA ratios at different time points were expressed as percentage to that at 0 min. Data are the mean &#177; SD of two independent experiments. Linear regression analysis was performed to compare the two treatment groups and statistically significant difference was found in the slope (<italic>P</italic> &lt; 0.05).</p>
###xml 8472 9326 8418 9257 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="33">Effect of APE1 knockdown on c-<italic>myc</italic> mRNA decay in HeLa cells. Twenty-four hours after plating at 1.0 &#215; 10<sup>5</sup> cells/well, cells were transfected with either 60 nM Control-dsRNAi or 60 nM APE1-dsRNAi. After a further 30 h incubation, cells were subjected to transcriptional inhibition by the addition of 200 &#181;M DRB. Total RNA was then extracted from cells after 20, 40 and 60 min of further incubation. c-<italic>myc</italic> and &#946;&#8211;actin mRNA levels were then quantified as described in <xref ref-type="fig" rid="F8">Figure 8</xref>. After normalizing the levels of c-<italic>myc</italic> mRNA to &#946;-actin mRNA, c-<italic>myc</italic>/&#946;-actin mRNA ratios at different time points were expressed as percentage to that at 0 min. Data are the mean &#177; SD of two independent experiments. Linear regression analysis was performed to compare the two treatment groups and statistically significant difference was found in the slope (<italic>P</italic> &lt; 0.05).</p></caption>
###xml 9326 9326 9257 9257 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp275f9"/>
###xml 8463 9326 8409 9257 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F9" position="float"><label>Figure 9.</label><caption><p textid="33">Effect of APE1 knockdown on c-<italic>myc</italic> mRNA decay in HeLa cells. Twenty-four hours after plating at 1.0 &#215; 10<sup>5</sup> cells/well, cells were transfected with either 60 nM Control-dsRNAi or 60 nM APE1-dsRNAi. After a further 30 h incubation, cells were subjected to transcriptional inhibition by the addition of 200 &#181;M DRB. Total RNA was then extracted from cells after 20, 40 and 60 min of further incubation. c-<italic>myc</italic> and &#946;&#8211;actin mRNA levels were then quantified as described in <xref ref-type="fig" rid="F8">Figure 8</xref>. After normalizing the levels of c-<italic>myc</italic> mRNA to &#946;-actin mRNA, c-<italic>myc</italic>/&#946;-actin mRNA ratios at different time points were expressed as percentage to that at 0 min. Data are the mean &#177; SD of two independent experiments. Linear regression analysis was performed to compare the two treatment groups and statistically significant difference was found in the slope (<italic>P</italic> &lt; 0.05).</p></caption><graphic xlink:href="gkp275f9"/></fig>
###xml 1504 1510 <span type="species:ncbi:9913">bovine</span>
###xml 2584 2590 <span type="species:ncbi:9913">bovine</span>
###xml 4260 4265 <span type="species:ncbi:9606">human</span>
###xml 4403 4408 <span type="species:ncbi:9606">human</span>
###xml 4728 4733 <span type="species:ncbi:9606">human</span>
###xml 4928 4933 <span type="species:ncbi:9606">human</span>
###xml 6093 6098 <span type="species:ncbi:9606">human</span>
###xml 6484 6489 <span type="species:ncbi:9606">human</span>
For statistical analysis, Student's t-test was performed for Figure 8 and linear regression analysis was performed for Figure 9 using Prism 3.0 software (GraphPad, Inc., San Diego, CA, USA). Figure 1.Purification and identification of proteins that co-purified with endoribonuclease activity. (A) Autoradiograph of an endoribonuclease assay in gel filtration fractions (elution volume 20-76) using 350 fmol 5' 32P-labeled CRD c-myc RNA as substrate. The endoribonuclease assay was performed for 5 min at 37degreesC under the standard condition as described in the 'Materials and Methods' section. Filled arrow indicates undigested substrate RNA and unfilled arrow indicates endonucleolytic decay products. (B) Silver-stained SDS-PAGE gel of pooled samples from gel filtration in (A). (C) Coomasie blue-stained SDS-PAGE gel of pooled samples from three separate gel filtration columns. Arrows indicate protein bands that were excised and subjected to LC-MS/MS protein identification analysis.Figure 2.Mapping the cleavage sites generated by the purified 17-kDa and 35-kDa native endoribonucleases. (A) Three hundred and fifty femtomole 5' -labeled c-myc CRD RNA were subjected to post-heparin-Sepharose purified enzyme (lanes 3 and 9), 30-40-kDa fraction purified enzyme (lanes 4-6 and 12 and 13) and 10-20-kDa fraction purified enzyme (lanes 10 and 11) from gel filtration column under the standard endoribonuclease assay. The radiolabeled RNA was also subjected to alkaline hydrolysis (lanes 7 and 14), bovine pancreatic RNase A (1 U) (lane 8), and RNase T1 digestion (1 U) (lane 1) as described previously (30,31). Samples were run on a 12% polyacrylamide/7 M urea gel. The amount of 30-40-kDa fraction purified enzyme used were 0.75 U (lane 4), 0.6 U (lane 5), 0.4 U (lane 6), 0.2 U (lane 12) and 0.1 U (lane 13). The amount of 10-20-kDa fraction purified enzyme used were 3 U (lane 10) and 1 U (lane 11). Asterisks indicate the 1751UA dinucleotide preferentially cleaved by the 30-40-kDa fraction enzyme. Arrows on the left indicate guanosine cleavage sites generated by RNase T1 and the numbers indicate position of nucleotide sequence. Numbers on the right indicate the cleavage sites generated by the endoribonucleases. (B) Secondary structure of c-myc CRD RNA and the cleavage sites generated by the 35-kDa endoribonuclease.Figure 3.Presence of RNase1 and APE1 in partially purified native enzyme. Western blot analysis of pooled samples from gel filtration (lanes 3-8) as detected by RNase A (upper panel) or APE1 (lower panel) antibody. Lane 1 contains 5 mug of recombinant bovine pancreatic RNase A.Figure 4.Immuno-depletion of the 35-kDa endoribonuclease activity using APE1 or syntaxin18 antibody. (A) Partially purified 35-kDa native enzyme was subjected to Seize X Protein A spin column which has been cross-linked with anti-APE1 antibody. Four microliters of washed (lanes 6 and 7) and eluted samples (lanes 8-10) were tested against 350 fmol 5'-labeled c-myc CRD RNA as described in 'Materials and Methods' section. Lane 1 contains the RNA only without any treatment with proteins. Lanes 2 and 3 contain 2 U and 3 U, respectively, of partially purified native enzyme from heparin-Sepharose column. Lanes 4 and 5 are 0.75 U and 1 U, respectively, of pre-loaded partially purified 30-40-kDa fraction native enzyme from gel filtration. Filled arrow indicates the intact c-myc CRD RNA and the decay products are shown with a bracket and unfilled arrow. (B) Western blot analysis of samples from (A) as detected using anti-APE1 antibody. Lane 1 contains 0.5 mug recombinant APE1 and lane 2 has the partially purified 30-40-kDa fraction native enzyme. FT is flow-through from the spin column. (C) As in (A), partially purified 35-kDa native enzyme was subjected to spin column which has been cross-linked with anti-syntaxin18 antibody. Lane 1 contains 2 U of partially purified native enzyme from heparin-Sepharose column. Four microliters of flow through (lane 2), washed (lane 3) and eluted samples (lanes 4 and 5) were tested against 5'-labeled c-myc CRD RNA as described in 'Materials and methods' section.Figure 5.Endoribonuclease activity of recombinant APE1 on c-myc CRD RNA. (A) Left panel, Coomasie blue-stained SDS-PAGE gel of recombinant human APE1 at 5 mug (lane 2) and 1 mug (lane 3). Lane 1 is molecular weight marker. Right panel, western blot analysis of 3 mug of recombinant human APE1 generated by us (lane 1) or in Dr. Hickson's laboratory (lane 2), as detected by specific monoclonal antibody against APE1. (B) Left panel, 350 fmol 5' -labeled c-myc CRD RNA were treated with 0.1 U of the partially purified 35-kDa native enzyme for 5 min (lanes 2 and 3), or with 0.05 mug of purified recombinant human APE1 generated in Dr. Hickson's laboratory (lane 4). Lane 1 had no protein added. Right panel, 350 fmol 5' -labeled c-myc CRD RNA were treated with 0.1 mug of purified and renatured recombinant human APE1 for 5 min (lane 2), 10 min (lane 3) and 20 min (lane 4), or with 0.1 U of the partially purified 35-kDa native enzyme for 5 min (lane 5), 10 min (lane 6) and 20 min (lane 7) under the standard endoribonuclease assay. Lane 1 had no protein added. Samples were run on 8% polyarylamide/7 M urea gel. Numbers on the right indicate cleavage sites generated by the enzymes.Figure 6.Endoribonuclease activity of recombinant APE1 polypeptide. (A) Left panel, 350 fmol 5' -labeled c-myc CRD RNA were treated with the purified and renatured wild-type APE1 (lanes 2 and 9), H309N (lanes 3-5) or E96A (lanes 6-8) mutant APE1 for 5 min at 37degreesC at the amount indicated under the standard endoribonuclease assay containing 20 mul reaction. Lanes 1 and 10, no protein added. Right panel, 350 fmol 5'-labeled c-myc CRD RNA were treated with the purified and renatured wild-type recombinant APE1 (lane 2) or N-terminus truncated APE1, ND42 (lane 3). Lane 1, no protein added. Samples were run on 8% polyarylamide/7 M urea gel. Numbers on the right indicate cleavage sites generated by the enzymes. (B) 5'-labeled c-myc CRD RNA were treated with purified recombinant human APE1 (lanes 2 and 3), HADHSC (lanes 4 and 5) or annexin3 (lanes 6 and 7) for 5 min at 37degreesC at the amount indicated under the standard endoribonuclease assay.Figure 7.APE1 is an endoribonuclease. c-myc CRD RNA corresponding to nts 1730-1766 was either 5'-labeled with 32P-gamma-ATP (A) or uniformly labeled with 32P-alpha-UTP (B) before subjecting to 0.1 mug purified recombinant human APE1 for 2 min (lane 2) or 5 min (lane 3) under the standard endoribonuclease assay. Samples were run on 8% polyarylamide/7 M urea gel. The secondary structure of RNA is on the right of each figure and arrows indicate the cleavage sites generated by APE1. Asterisks on the structure in (B) indicate radiolabeled uridine. Schematic RNA secondary structures on the right represent 5'fragment of cleavage products while those on the left in (B) represent 3'fragment of cleavage products. (C) 5'-labeled oligonucleotide corresponding to nts 1742-1757 of c-myc CRD was treated for 5 min with increasing concentrations (0.08-0.8 mug) of recombinant APE1 (lanes 3-9) or with 2 U partially purified native APE1 from heparin sepharose column (lane 2). Samples were run on 12% polyarylamide/7 M urea gel. The secondary structure of the oligo is on the right panel and the arrow indicates the RNA cleavage site generated by APE1. Schematic secondary structures on the right represent the full-length oligo (top) or 5'fragment of the cleavage product (bottom).Figure 8.APE1 knockdown increases c-myc mRNA level in HeLa cells. (A) Western blot analysis of APE1 and beta-actin protein levels in HeLa cells at 24 and 48 h after transfection with 20 muM Control-dsRNAi or 20 muM APE1-dsRNAi. (B) APE1 and beta-actin mRNA levels in HeLa cells transfected with 20 muM APE1-dsRNAi or 20 muM Control-dsRNAi for 24 and 48 h were analyzed by quantitative real-time RT-PCR (top panel). CT values obtained in triplicates from separate transfection experiments were used in the comparative CT method calculation as described in 'Materials and Methods' section. Data are mean +/- SD of three independent experiments (*, P < 0.05). The APE1/beta-actin mRNA ratios are presented as a percentage relative to Control-dsRNAi (top panel). The same RNA samples were analyzed for c-myc mRNA levels and the c-myc/beta-actin mRNA ratios are presented as a percentage relative to Control-dsRNAi (bottom panel).Figure 9.Effect of APE1 knockdown on c-myc mRNA decay in HeLa cells. Twenty-four hours after plating at 1.0 x 105 cells/well, cells were transfected with either 60 nM Control-dsRNAi or 60 nM APE1-dsRNAi. After a further 30 h incubation, cells were subjected to transcriptional inhibition by the addition of 200 microM DRB. Total RNA was then extracted from cells after 20, 40 and 60 min of further incubation. c-myc and beta-actin mRNA levels were then quantified as described in Figure 8. After normalizing the levels of c-myc mRNA to beta-actin mRNA, c-myc/beta-actin mRNA ratios at different time points were expressed as percentage to that at 0 min. Data are the mean +/- SD of two independent experiments. Linear regression analysis was performed to compare the two treatment groups and statistically significant difference was found in the slope (P < 0.05).
###end p 24
###begin p 25
###xml 94 95 94 95 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 210 212 210 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 228 231 228 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 507 508 501 502 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 585 586 579 580 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
Purification and identification of proteins that co-purified with endoribonuclease activity. (A) Autoradiograph of an endoribonuclease assay in gel filtration fractions (elution volume 20-76) using 350 fmol 5' 32P-labeled CRD c-myc RNA as substrate. The endoribonuclease assay was performed for 5 min at 37degreesC under the standard condition as described in the 'Materials and Methods' section. Filled arrow indicates undigested substrate RNA and unfilled arrow indicates endonucleolytic decay products. (B) Silver-stained SDS-PAGE gel of pooled samples from gel filtration in (A). (C) Coomasie blue-stained SDS-PAGE gel of pooled samples from three separate gel filtration columns. Arrows indicate protein bands that were excised and subjected to LC-MS/MS protein identification analysis.
###end p 25
###begin p 26
###xml 98 99 98 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 149 152 149 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 612 614 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 1228 1229 1228 1229 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1256 1259 1256 1259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 504 510 <span type="species:ncbi:9913">bovine</span>
Mapping the cleavage sites generated by the purified 17-kDa and 35-kDa native endoribonucleases. (A) Three hundred and fifty femtomole 5' -labeled c-myc CRD RNA were subjected to post-heparin-Sepharose purified enzyme (lanes 3 and 9), 30-40-kDa fraction purified enzyme (lanes 4-6 and 12 and 13) and 10-20-kDa fraction purified enzyme (lanes 10 and 11) from gel filtration column under the standard endoribonuclease assay. The radiolabeled RNA was also subjected to alkaline hydrolysis (lanes 7 and 14), bovine pancreatic RNase A (1 U) (lane 8), and RNase T1 digestion (1 U) (lane 1) as described previously (30,31). Samples were run on a 12% polyacrylamide/7 M urea gel. The amount of 30-40-kDa fraction purified enzyme used were 0.75 U (lane 4), 0.6 U (lane 5), 0.4 U (lane 6), 0.2 U (lane 12) and 0.1 U (lane 13). The amount of 10-20-kDa fraction purified enzyme used were 3 U (lane 10) and 1 U (lane 11). Asterisks indicate the 1751UA dinucleotide preferentially cleaved by the 30-40-kDa fraction enzyme. Arrows on the left indicate guanosine cleavage sites generated by RNase T1 and the numbers indicate position of nucleotide sequence. Numbers on the right indicate the cleavage sites generated by the endoribonucleases. (B) Secondary structure of c-myc CRD RNA and the cleavage sites generated by the 35-kDa endoribonuclease.
###end p 26
###begin p 27
###xml 243 249 <span type="species:ncbi:9913">bovine</span>
Presence of RNase1 and APE1 in partially purified native enzyme. Western blot analysis of pooled samples from gel filtration (lanes 3-8) as detected by RNase A (upper panel) or APE1 (lower panel) antibody. Lane 1 contains 5 mug of recombinant bovine pancreatic RNase A.
###end p 27
###begin p 28
###xml 93 94 93 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 353 356 353 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 767 770 767 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 848 849 848 849 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1086 1087 1085 1086 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1442 1445 1441 1444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
Immuno-depletion of the 35-kDa endoribonuclease activity using APE1 or syntaxin18 antibody. (A) Partially purified 35-kDa native enzyme was subjected to Seize X Protein A spin column which has been cross-linked with anti-APE1 antibody. Four microliters of washed (lanes 6 and 7) and eluted samples (lanes 8-10) were tested against 350 fmol 5'-labeled c-myc CRD RNA as described in 'Materials and Methods' section. Lane 1 contains the RNA only without any treatment with proteins. Lanes 2 and 3 contain 2 U and 3 U, respectively, of partially purified native enzyme from heparin-Sepharose column. Lanes 4 and 5 are 0.75 U and 1 U, respectively, of pre-loaded partially purified 30-40-kDa fraction native enzyme from gel filtration. Filled arrow indicates the intact c-myc CRD RNA and the decay products are shown with a bracket and unfilled arrow. (B) Western blot analysis of samples from (A) as detected using anti-APE1 antibody. Lane 1 contains 0.5 mug recombinant APE1 and lane 2 has the partially purified 30-40-kDa fraction native enzyme. FT is flow-through from the spin column. (C) As in (A), partially purified 35-kDa native enzyme was subjected to spin column which has been cross-linked with anti-syntaxin18 antibody. Lane 1 contains 2 U of partially purified native enzyme from heparin-Sepharose column. Four microliters of flow through (lane 2), washed (lane 3) and eluted samples (lanes 4 and 5) were tested against 5'-labeled c-myc CRD RNA as described in 'Materials and methods' section.
###end p 28
###begin p 29
###xml 51 54 51 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 65 66 65 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 409 410 406 407 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 447 450 444 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 722 725 718 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 130 135 <span type="species:ncbi:9606">human</span>
###xml 273 278 <span type="species:ncbi:9606">human</span>
###xml 598 603 <span type="species:ncbi:9606">human</span>
###xml 798 803 <span type="species:ncbi:9606">human</span>
Endoribonuclease activity of recombinant APE1 on c-myc CRD RNA. (A) Left panel, Coomasie blue-stained SDS-PAGE gel of recombinant human APE1 at 5 mug (lane 2) and 1 mug (lane 3). Lane 1 is molecular weight marker. Right panel, western blot analysis of 3 mug of recombinant human APE1 generated by us (lane 1) or in Dr. Hickson's laboratory (lane 2), as detected by specific monoclonal antibody against APE1. (B) Left panel, 350 fmol 5' -labeled c-myc CRD RNA were treated with 0.1 U of the partially purified 35-kDa native enzyme for 5 min (lanes 2 and 3), or with 0.05 mug of purified recombinant human APE1 generated in Dr. Hickson's laboratory (lane 4). Lane 1 had no protein added. Right panel, 350 fmol 5' -labeled c-myc CRD RNA were treated with 0.1 mug of purified and renatured recombinant human APE1 for 5 min (lane 2), 10 min (lane 3) and 20 min (lane 4), or with 0.1 U of the partially purified 35-kDa native enzyme for 5 min (lane 5), 10 min (lane 6) and 20 min (lane 7) under the standard endoribonuclease assay. Lane 1 had no protein added. Samples were run on 8% polyarylamide/7 M urea gel. Numbers on the right indicate cleavage sites generated by the enzymes.
###end p 29
###begin p 30
###xml 60 61 60 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 98 101 98 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 424 427 417 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 711 712 704 705 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 727 730 720 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 778 783 <span type="species:ncbi:9606">human</span>
Endoribonuclease activity of recombinant APE1 polypeptide. (A) Left panel, 350 fmol 5' -labeled c-myc CRD RNA were treated with the purified and renatured wild-type APE1 (lanes 2 and 9), H309N (lanes 3-5) or E96A (lanes 6-8) mutant APE1 for 5 min at 37degreesC at the amount indicated under the standard endoribonuclease assay containing 20 mul reaction. Lanes 1 and 10, no protein added. Right panel, 350 fmol 5'-labeled c-myc CRD RNA were treated with the purified and renatured wild-type recombinant APE1 (lane 2) or N-terminus truncated APE1, ND42 (lane 3). Lane 1, no protein added. Samples were run on 8% polyarylamide/7 M urea gel. Numbers on the right indicate cleavage sites generated by the enzymes. (B) 5'-labeled c-myc CRD RNA were treated with purified recombinant human APE1 (lanes 2 and 3), HADHSC (lanes 4 and 5) or annexin3 (lanes 6 and 7) for 5 min at 37degreesC at the amount indicated under the standard endoribonuclease assay.
###end p 30
###begin p 31
###xml 31 34 31 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 101 103 101 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 145 147 141 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 160 161 152 153 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 705 706 696 697 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 771 774 762 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 213 218 <span type="species:ncbi:9606">human</span>
APE1 is an endoribonuclease. c-myc CRD RNA corresponding to nts 1730-1766 was either 5'-labeled with 32P-gamma-ATP (A) or uniformly labeled with 32P-alpha-UTP (B) before subjecting to 0.1 mug purified recombinant human APE1 for 2 min (lane 2) or 5 min (lane 3) under the standard endoribonuclease assay. Samples were run on 8% polyarylamide/7 M urea gel. The secondary structure of RNA is on the right of each figure and arrows indicate the cleavage sites generated by APE1. Asterisks on the structure in (B) indicate radiolabeled uridine. Schematic RNA secondary structures on the right represent 5'fragment of cleavage products while those on the left in (B) represent 3'fragment of cleavage products. (C) 5'-labeled oligonucleotide corresponding to nts 1742-1757 of c-myc CRD was treated for 5 min with increasing concentrations (0.08-0.8 mug) of recombinant APE1 (lanes 3-9) or with 2 U partially purified native APE1 from heparin sepharose column (lane 2). Samples were run on 12% polyarylamide/7 M urea gel. The secondary structure of the oligo is on the right panel and the arrow indicates the RNA cleavage site generated by APE1. Schematic secondary structures on the right represent the full-length oligo (top) or 5'fragment of the cleavage product (bottom).
###end p 31
###begin p 32
###xml 27 30 27 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 58 59 58 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 220 221 215 216 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 407 408 397 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 509 510 499 500 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 637 638 625 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 791 794 776 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 817 820 802 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
APE1 knockdown increases c-myc mRNA level in HeLa cells. (A) Western blot analysis of APE1 and beta-actin protein levels in HeLa cells at 24 and 48 h after transfection with 20 muM Control-dsRNAi or 20 muM APE1-dsRNAi. (B) APE1 and beta-actin mRNA levels in HeLa cells transfected with 20 muM APE1-dsRNAi or 20 muM Control-dsRNAi for 24 and 48 h were analyzed by quantitative real-time RT-PCR (top panel). CT values obtained in triplicates from separate transfection experiments were used in the comparative CT method calculation as described in 'Materials and Methods' section. Data are mean +/- SD of three independent experiments (*, P < 0.05). The APE1/beta-actin mRNA ratios are presented as a percentage relative to Control-dsRNAi (top panel). The same RNA samples were analyzed for c-myc mRNA levels and the c-myc/beta-actin mRNA ratios are presented as a percentage relative to Control-dsRNAi (bottom panel).
###end p 32
###begin p 33
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 103 104 103 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 403 406 399 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 471 479 464 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 515 518 508 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 546 549 536 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 844 845 829 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Effect of APE1 knockdown on c-myc mRNA decay in HeLa cells. Twenty-four hours after plating at 1.0 x 105 cells/well, cells were transfected with either 60 nM Control-dsRNAi or 60 nM APE1-dsRNAi. After a further 30 h incubation, cells were subjected to transcriptional inhibition by the addition of 200 microM DRB. Total RNA was then extracted from cells after 20, 40 and 60 min of further incubation. c-myc and beta-actin mRNA levels were then quantified as described in Figure 8. After normalizing the levels of c-myc mRNA to beta-actin mRNA, c-myc/beta-actin mRNA ratios at different time points were expressed as percentage to that at 0 min. Data are the mean +/- SD of two independent experiments. Linear regression analysis was performed to compare the two treatment groups and statistically significant difference was found in the slope (P < 0.05).
###end p 33
###begin title 34
RESULTS
###end title 34
###begin title 35
Purification and identification of the 35-kDa liver endoribonuclease
###end title 35
###begin p 36
###xml 101 104 101 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 566 574 554 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 650 658 638 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 936 944 912 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 988 996 964 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1343 1350 1319 1326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 1571 1579 1547 1555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1873 1875 1849 1851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 1974 1977 1950 1953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 1983 1985 1959 1961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 2228 2236 2204 2212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 2383 2388 2359 2364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37 B38 B39">37&#8211;39</xref>
###xml 2733 2741 2709 2717 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1.</label>
###xml 2741 2856 2717 2832 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="37">Summary of LC/MS mass spectrometry data and peptide analysis to identify purified proteins following gel filtration</p>
###xml 2741 2856 2717 2832 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="37">Summary of LC/MS mass spectrometry data and peptide analysis to identify purified proteins following gel filtration</p></caption>
###xml 2856 2870 2832 2846 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Protein band #</th>
###xml 2901 2909 2877 2885 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rodentia</italic>
###xml 2870 2917 2846 2893 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Top three protein matches from <italic>Rodentia</italic> species</th>
###xml 2917 2944 2893 2920 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Amino sequence coverage (%)</th>
###xml 2944 2970 2920 2946 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Number of matched peptides</th>
###xml 2856 2970 2832 2946 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><th rowspan="1" colspan="1">Protein band #</th><th rowspan="1" colspan="1">Top three protein matches from <italic>Rodentia</italic> species</th><th rowspan="1" colspan="1">Amino sequence coverage (%)</th><th rowspan="1" colspan="1">Number of matched peptides</th></tr>
###xml 2856 2970 2832 2946 <thead xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left"><tr><th rowspan="1" colspan="1">Protein band #</th><th rowspan="1" colspan="1">Top three protein matches from <italic>Rodentia</italic> species</th><th rowspan="1" colspan="1">Amino sequence coverage (%)</th><th rowspan="1" colspan="1">Number of matched peptides</th></tr></thead>
###xml 2970 2971 2946 2947 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1</td>
###xml 2971 3048 2947 3024 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1) Apurinic/apyrimidinic endonuclease lyase (AP endonuclease/APE1) (35.8 kDa)</td>
###xml 3048 3054 3024 3030 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1) 32%</td>
###xml 3054 3058 3030 3034 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1) 7</td>
###xml 2970 3058 2946 3034 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1) Apurinic/apyrimidinic endonuclease lyase (AP endonuclease/APE1) (35.8 kDa)</td><td rowspan="1" colspan="1">1) 32%</td><td rowspan="1" colspan="1">1) 7</td></tr>
###xml 3058 3058 3034 3034 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 3058 3083 3034 3059 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">2) Annexin III (36.5 kDa)</td>
###xml 3083 3089 3059 3065 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">2) 38%</td>
###xml 3089 3094 3065 3070 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">2) 10</td>
###xml 3058 3094 3034 3070 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2) Annexin III (36.5 kDa)</td><td rowspan="1" colspan="1">2) 38%</td><td rowspan="1" colspan="1">2) 10</td></tr>
###xml 3094 3094 3070 3070 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 3094 3130 3070 3106 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">3) Aldo-keto reductase E1 (34.8 kDa)</td>
###xml 3130 3136 3106 3112 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">3) 40%</td>
###xml 3136 3141 3112 3117 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">3) 11</td>
###xml 3094 3141 3070 3117 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3) Aldo-keto reductase E1 (34.8 kDa)</td><td rowspan="1" colspan="1">3) 40%</td><td rowspan="1" colspan="1">3) 11</td></tr>
###xml 3141 3142 3117 3118 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">2</td>
###xml 3142 3193 3118 3169 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">L-3-hydroxyacyl-CoA dehydrogenase (HADHSC) (34 kDa)</td>
###xml 3193 3196 3169 3172 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">55%</td>
###xml 3196 3197 3172 3173 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">8</td>
###xml 3141 3197 3117 3173 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">L-3-hydroxyacyl-CoA dehydrogenase (HADHSC) (34 kDa)</td><td rowspan="1" colspan="1">55%</td><td rowspan="1" colspan="1">8</td></tr>
###xml 3197 3198 3173 3174 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">3</td>
###xml 3198 3252 3174 3228 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1) Peroxisomal enoyl hydratase-like protein (36.5 kDa)</td>
###xml 3252 3258 3228 3234 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1) 46%</td>
###xml 3258 3263 3234 3239 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1) 12</td>
###xml 3197 3263 3173 3239 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">1) Peroxisomal enoyl hydratase-like protein (36.5 kDa)</td><td rowspan="1" colspan="1">1) 46%</td><td rowspan="1" colspan="1">1) 12</td></tr>
###xml 3263 3263 3239 3239 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 3263 3281 3239 3257 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">2) HADHSC (34 kDa)</td>
###xml 3281 3287 3257 3263 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">2) 20%</td>
###xml 3287 3291 3263 3267 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">2) 3</td>
###xml 3263 3291 3239 3267 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2) HADHSC (34 kDa)</td><td rowspan="1" colspan="1">2) 20%</td><td rowspan="1" colspan="1">2) 3</td></tr>
###xml 3291 3291 3267 3267 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 3291 3330 3267 3306 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">3) Glutathione S-transferase (25.6 kDa)</td>
###xml 3330 3336 3306 3312 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">3) 54%</td>
###xml 3336 3340 3312 3316 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">3) 7</td>
###xml 3291 3340 3267 3316 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3) Glutathione S-transferase (25.6 kDa)</td><td rowspan="1" colspan="1">3) 54%</td><td rowspan="1" colspan="1">3) 7</td></tr>
###xml 3340 3341 3316 3317 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">4</td>
###xml 3341 3363 3317 3339 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Cyclophilin B (23 kDa)</td>
###xml 3363 3366 3339 3342 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">56%</td>
###xml 3366 3368 3342 3344 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">14</td>
###xml 3340 3368 3316 3344 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">Cyclophilin B (23 kDa)</td><td rowspan="1" colspan="1">56%</td><td rowspan="1" colspan="1">14</td></tr>
###xml 3368 3369 3344 3345 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">5</td>
###xml 3369 3412 3345 3388 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Pancreatic ribonuclease A (RNase1) (17 kDa)</td>
###xml 3412 3415 3388 3391 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">45%</td>
###xml 3415 3416 3391 3392 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">5</td>
###xml 3368 3416 3344 3392 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Pancreatic ribonuclease A (RNase1) (17 kDa)</td><td rowspan="1" colspan="1">45%</td><td rowspan="1" colspan="1">5</td></tr>
###xml 3416 3417 3392 3393 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">6</td>
###xml 3417 3440 3393 3416 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Cytochrome C (12.5 kDa)</td>
###xml 3440 3443 3416 3419 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">55%</td>
###xml 3443 3445 3419 3421 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">11</td>
###xml 3416 3445 3392 3421 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">Cytochrome C (12.5 kDa)</td><td rowspan="1" colspan="1">55%</td><td rowspan="1" colspan="1">11</td></tr>
###xml 2970 3445 2946 3421 <tbody xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left"><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1) Apurinic/apyrimidinic endonuclease lyase (AP endonuclease/APE1) (35.8 kDa)</td><td rowspan="1" colspan="1">1) 32%</td><td rowspan="1" colspan="1">1) 7</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2) Annexin III (36.5 kDa)</td><td rowspan="1" colspan="1">2) 38%</td><td rowspan="1" colspan="1">2) 10</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3) Aldo-keto reductase E1 (34.8 kDa)</td><td rowspan="1" colspan="1">3) 40%</td><td rowspan="1" colspan="1">3) 11</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">L-3-hydroxyacyl-CoA dehydrogenase (HADHSC) (34 kDa)</td><td rowspan="1" colspan="1">55%</td><td rowspan="1" colspan="1">8</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">1) Peroxisomal enoyl hydratase-like protein (36.5 kDa)</td><td rowspan="1" colspan="1">1) 46%</td><td rowspan="1" colspan="1">1) 12</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2) HADHSC (34 kDa)</td><td rowspan="1" colspan="1">2) 20%</td><td rowspan="1" colspan="1">2) 3</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3) Glutathione S-transferase (25.6 kDa)</td><td rowspan="1" colspan="1">3) 54%</td><td rowspan="1" colspan="1">3) 7</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">Cyclophilin B (23 kDa)</td><td rowspan="1" colspan="1">56%</td><td rowspan="1" colspan="1">14</td></tr><tr><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Pancreatic ribonuclease A (RNase1) (17 kDa)</td><td rowspan="1" colspan="1">45%</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">Cytochrome C (12.5 kDa)</td><td rowspan="1" colspan="1">55%</td><td rowspan="1" colspan="1">11</td></tr></tbody>
###xml 2856 3445 2832 3421 <table xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">Protein band #</th><th rowspan="1" colspan="1">Top three protein matches from <italic>Rodentia</italic> species</th><th rowspan="1" colspan="1">Amino sequence coverage (%)</th><th rowspan="1" colspan="1">Number of matched peptides</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1) Apurinic/apyrimidinic endonuclease lyase (AP endonuclease/APE1) (35.8 kDa)</td><td rowspan="1" colspan="1">1) 32%</td><td rowspan="1" colspan="1">1) 7</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2) Annexin III (36.5 kDa)</td><td rowspan="1" colspan="1">2) 38%</td><td rowspan="1" colspan="1">2) 10</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3) Aldo-keto reductase E1 (34.8 kDa)</td><td rowspan="1" colspan="1">3) 40%</td><td rowspan="1" colspan="1">3) 11</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">L-3-hydroxyacyl-CoA dehydrogenase (HADHSC) (34 kDa)</td><td rowspan="1" colspan="1">55%</td><td rowspan="1" colspan="1">8</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">1) Peroxisomal enoyl hydratase-like protein (36.5 kDa)</td><td rowspan="1" colspan="1">1) 46%</td><td rowspan="1" colspan="1">1) 12</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2) HADHSC (34 kDa)</td><td rowspan="1" colspan="1">2) 20%</td><td rowspan="1" colspan="1">2) 3</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3) Glutathione S-transferase (25.6 kDa)</td><td rowspan="1" colspan="1">3) 54%</td><td rowspan="1" colspan="1">3) 7</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">Cyclophilin B (23 kDa)</td><td rowspan="1" colspan="1">56%</td><td rowspan="1" colspan="1">14</td></tr><tr><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Pancreatic ribonuclease A (RNase1) (17 kDa)</td><td rowspan="1" colspan="1">45%</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">Cytochrome C (12.5 kDa)</td><td rowspan="1" colspan="1">55%</td><td rowspan="1" colspan="1">11</td></tr></tbody></table>
###xml 2733 3445 2709 3421 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="T1" position="float"><label>Table 1.</label><caption><p textid="37">Summary of LC/MS mass spectrometry data and peptide analysis to identify purified proteins following gel filtration</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">Protein band #</th><th rowspan="1" colspan="1">Top three protein matches from <italic>Rodentia</italic> species</th><th rowspan="1" colspan="1">Amino sequence coverage (%)</th><th rowspan="1" colspan="1">Number of matched peptides</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1) Apurinic/apyrimidinic endonuclease lyase (AP endonuclease/APE1) (35.8 kDa)</td><td rowspan="1" colspan="1">1) 32%</td><td rowspan="1" colspan="1">1) 7</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2) Annexin III (36.5 kDa)</td><td rowspan="1" colspan="1">2) 38%</td><td rowspan="1" colspan="1">2) 10</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3) Aldo-keto reductase E1 (34.8 kDa)</td><td rowspan="1" colspan="1">3) 40%</td><td rowspan="1" colspan="1">3) 11</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">L-3-hydroxyacyl-CoA dehydrogenase (HADHSC) (34 kDa)</td><td rowspan="1" colspan="1">55%</td><td rowspan="1" colspan="1">8</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">1) Peroxisomal enoyl hydratase-like protein (36.5 kDa)</td><td rowspan="1" colspan="1">1) 46%</td><td rowspan="1" colspan="1">1) 12</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2) HADHSC (34 kDa)</td><td rowspan="1" colspan="1">2) 20%</td><td rowspan="1" colspan="1">2) 3</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3) Glutathione S-transferase (25.6 kDa)</td><td rowspan="1" colspan="1">3) 54%</td><td rowspan="1" colspan="1">3) 7</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">Cyclophilin B (23 kDa)</td><td rowspan="1" colspan="1">56%</td><td rowspan="1" colspan="1">14</td></tr><tr><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Pancreatic ribonuclease A (RNase1) (17 kDa)</td><td rowspan="1" colspan="1">45%</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">Cytochrome C (12.5 kDa)</td><td rowspan="1" colspan="1">55%</td><td rowspan="1" colspan="1">11</td></tr></tbody></table></table-wrap>
###xml 72 75 <span type="species:ncbi:10116">rat</span>
###xml 1966 1971 <span type="species:ncbi:9606">human</span>
We previously reported partial purification of an endoribonuclease from rat liver for cleaving the c-myc CRD RNA (30). Five major proteins of approximately10-35-kDa size were co-purified with this activity. To determine the identity of the responsible enzyme, we first repeated earlier enzyme purification steps with slight modifications as described in the 'Materials and Methods' section. Two endoribonuclease activities from the final gel filtration column at elution volumes 46-50 ml and 62-68 ml, corresponding to 30-40-kDa and 10-20-kDa sizes, were prominent (Figure 1A). Pooled protein fractions visualized by silver-staining in SDS-PAGE gel (Figure 1B) shows a distinct protein band of approximately35 kDa at elution volume 40-50 ml and four protein bands from 10-20 kDa at elution volume 60-66 ml. These fractions were separately pooled from three separate preparations and visualized by Coomasie blue-staining after SDS-PAGE (Figure 1C). Gel slices at around protein bands 1-6 (Figure 1C) were excised for LC/MS mass spectrometry protein identification analysis at the Genome BC Proteomics Centre, University of Victoria. Based on molecular weight of proteins, number of matched peptides, and percentage of amino acid sequence against the 'rodentia' protein database, the top three proteins that matched for each band were selected (Table 1). The three major proteins, L-3-hydroxyacyl-CoA dehydrogenase (HADHSC), annexin III and AP endonuclease (APE1), were identified as possible candidates for the 35-kDa endoribonuclease. The band in between band 2 and 3 in Figure 1C was determined to be HADHSC by LC/MS spectrometry (data not shown). This band may in fact represent a truncated or non-post-translationally modified form of HADHSC. In addition to the criteria described above, HADHSC was chosen because it contains a predicted RNA-binding Rossman fold motif (35) and annexin III was chosen because a related protein, annexin II, has been shown to bind human c-myc RNA (36). Both HADHSC and annexin III were present in the gel filtration fractions as determined by western analysis (data not shown). However, neither purified recombinant HADHSC nor annexin III exhibited any endoribonuclease activity (see later in Figure 6B). APE1 then became the prime candidate because it is a known multifunctional protein with DNA-specific endonuclease and RNase H-like activities (37-39). To further confirm its identity, we performed duplicate LC/MS mass spectrometry on individual 35-38-kDa protein in the gel slices isolated after heparin-Sepharose chromatography. Both HADHSC and APE1 were again two of the matched proteins (data not shown), suggesting that both proteins co-purified with the 35-kDa endoribonuclease activity. Table 1.Summary of LC/MS mass spectrometry data and peptide analysis to identify purified proteins following gel filtrationProtein band #Top three protein matches from Rodentia speciesAmino sequence coverage (%)Number of matched peptides11) Apurinic/apyrimidinic endonuclease lyase (AP endonuclease/APE1) (35.8 kDa)1) 32%1) 72) Annexin III (36.5 kDa)2) 38%2) 103) Aldo-keto reductase E1 (34.8 kDa)3) 40%3) 112L-3-hydroxyacyl-CoA dehydrogenase (HADHSC) (34 kDa)55%831) Peroxisomal enoyl hydratase-like protein (36.5 kDa)1) 46%1) 122) HADHSC (34 kDa)2) 20%2) 33) Glutathione S-transferase (25.6 kDa)3) 54%3) 74Cyclophilin B (23 kDa)56%145Pancreatic ribonuclease A (RNase1) (17 kDa)45%56Cytochrome C (12.5 kDa)55%11
###end p 36
###begin p 37
Summary of LC/MS mass spectrometry data and peptide analysis to identify purified proteins following gel filtration
###end p 37
###begin title 38
The 17-kDa endoribonuclease belongs to the RNase A superfamily
###end title 38
###begin p 39
###xml 70 78 70 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 211 218 211 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 714 722 714 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 889 897 889 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 952 960 952 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1044 1052 1044 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 139 142 <span type="species:ncbi:10116">rat</span>
###xml 650 656 <span type="species:ncbi:9913">bovine</span>
Based on the above identification criteria, protein bands 4, 5 and 6 (Figure 1C) were convincingly identified as cyclophilin B, pancreatic rat ribonuclease A family member RNase1, and cytochrome c respectively (Table 1). We reasoned that the 17-kDa RNase 1 is most likely responsible for the 10-20-kDa endoribonuclease activity based on the following observations: (i) RNase 1 is the only known protein with ribonuclease activity identified from 10-20-kDa protein bands 4, 5 and 6, (ii) RNA sequence cleavage specificity of the partially purified 10-20-kDa native enzyme from gel filtration resembled, yet was not identical, to that exhibited by the bovine pancreatic RNase A (compare lanes 10 and 11 to lane 8 in Figure 2A), and (iii) polyclonal antibody against RNase A detected a protein band at around 17-kDa range in elution volume 60-80 ml from gel filtration column (lanes 7 and 8, Figure 3) which correlated with the endoribonuclease activity (Figure 1A), and finally the presence of 17-kDa protein band on silver-stained SDS-PAGE gel (Figure 1B).
###end p 39
###begin title 40
The 35-kDa endoribonuclease activity is not attributable to a modified form of pancreatic RNase A
###end title 40
###begin p 41
###xml 24 27 24 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 445 453 445 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 600 608 600 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 702 710 702 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
The cleavage sites on c-myc CRD RNA generated by the purified native enzyme in the heparin-Sepharose and gel filtration fractions with proteins of 10-20-kDa and 30-40-kDa size range were mapped as previously described using RNase T1 digest and alkaline hydrolysis (30,31). The 30-40-kDa fraction appeared to exhibit similarity with the 10-20-kDa fractions in sequence cleavage specificity (compare lanes 4, 5, 6, 12 and 13 with lanes 10 and 11, Figure 2A). However, there were some differences in that the 30-40-kDa fractions had stronger preference for the 1751UA dinucleotide (shown by asterisks) (Figure 2A). The 30-40-kDa fractions also had some preference for the 1771CA and 1773UA dinucleotides (Figure 2A).
###end p 41
###begin p 42
###xml 230 238 230 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 578 580 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 921 929 921 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
Given the similarity in RNA cleavage patterns between the 30-40-kDa and the 10-20-kDa fractions, together with the observations that the polyclonal antibody against RNase A detected a faint band corresponding to 30-kDa (lane 6 in Figure 3) and 35-kDa (data not shown) polypeptides on western blots, we considered whether the 30-40-kDa endoribonuclease activity is contributed by a modified form of pancreatic RNase A. This is plausible because the dimeric RNase A is known to exist (40), and a monomeric N-glycosylated RNase A of approximately 24-36-kDa size has been reported (41). To test the possibility that the 35-kDa endoribonuclease is a disulfide-linked dimeric RNase A, we treated the purified post-heparin Sepharose fraction with 250 mM DTT before gel filtration analysis. Endoribonuclease analysis of the fractions showed two distinct activities (data not shown) similar to the profile of the original sample (Figure 1A). We therefore concluded that the 35-kDa endoribonuclease is unlikely to be a disulfide-linked dimeric form of 17-kDa RNase1, and is likely a monomeric protein. To test the possibility that the 35-kDa endoribonuclease is a N-glycosylated RNase A, we treated the heparin Sepharose fraction with 100 U endoglycosidase F before gel filtration chromatography. Our results (data not shown) show that the elution profile of endoribonuclease activity remained unchanged compared to the original sample. Thus, the 35-kDa endoribonuclease is unlikely to be N-glycosylated RNase A.
###end p 42
###begin title 43
Immuno-depletion of the 35-kDa endoribonuclease with APE1 monoclonal antibody
###end title 43
###begin p 44
###xml 160 168 160 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 241 249 241 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 325 333 325 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 552 560 552 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 951 959 951 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1064 1072 1064 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1304 1312 1304 1312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1342 1350 1342 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1530 1538 1530 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1562 1570 1562 1570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1789 1797 1789 1797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 2164 2172 2164 2172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
Our results so far suggested that the 35-kDa endoribonuclease was APE1 which we then tested by western analysis of the 30-40-kDa fractions from gel filtration. Figure 3 shows that APE1 is present only in the elution volume 45-55 ml (lane 6, Figure 3, bottom panel) which correlates with the 35-kDa endoribonuclease activity (Figure 1A). We performed immunodepletion studies of the purified native 35-kDa endoribonuclease with the APE1 antibody. Endoribonuclease analysis of the fractions eluted from an APE1 monoclonal antibody spin column is shown in Figure 4A. Washed fractions (lanes 6 and 7) had no endoribonuclease activity while the earlier elution fractions (lanes 8 and 9) contained endoribonuclease activity. Endoribonuclease activity in Elution 1 (lane 8) was as high as those from partially purified post-heparin-Sepharose sample (lanes 2 and 3). In both cases, excess nuclease activity led to almost complete degradation of RNA substrate. Figure 4B shows western blot analysis of samples taken from the same immunoprecipitation experiment described in Figure 4A. There was striking correlation between the endoribonuclease activity in the pre-loaded purified native 30-40-kDa gel filtration fraction, Elutions 1 and 2, and the presence of APE1 in those fractions (compare lanes 2, 6 and 7 in Figure 4B with lanes 4, 5, 8 and 9 in Figure 4A). In addition, there was correlation between the absence of endoribonuclease activity in the wash fractions, and the absence of APE1 in those fractions (compare lanes 4 and 5 in Figure 4B with lanes 6 and 7 in Figure 4A). To confirm the specificity of the immunodepletion experiment using APE1 antibody, we performed similar experiments using another antibody cross-linked to the spin column, which in this case was syntaxin18 antibody. Figure 4C shows that endoribonuclease analysis of the fractions eluted from syntaxin18 antibody spin column. The flow through (lane 2) and washed fractions (lane 3) showed strong nuclease activity whereas the Elution 1 and 2 (lanes 4 and 5) had no endoribonuclease activity. This control experiment confirmed that the immunodepletion of endoribonuclease activity observed in Figure 4A was produced specifically by the presence of anti-APE1 antibody.
###end p 44
###begin title 45
###xml 12 17 <span type="species:ncbi:9606">human</span>
Recombinant human APE1 and purified native 35-kDa endoribonuclease exhibited similar RNA cleavage pattern
###end title 45
###begin p 46
###xml 101 104 101 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 231 239 231 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 296 304 296 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 385 393 385 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 431 439 431 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 842 845 842 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 910 918 910 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1137 1145 1137 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1196 1204 1196 1204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 48 53 <span type="species:ncbi:9606">human</span>
We then directly tested whether the recombinant human APE1 possesses endoribonuclease activity for c-myc CRD RNA. The purified proteins were almost homogenous with more than 95% pure based on Coomasie blue-staining after SDS-PAGE (Figure 5A, left panel) and identity checked by western analysis (Figure 5A, right panel). The minor, lower-molecular-weight band in the immunoblot assay (Figure 5A, right panel) and the SDS-PAGE gel (Figure 5A, lane 2 in left panel) was likely to be a N-terminal cleavage product of APE1 (42). This is commonly observed as the protein is quite susceptible to specific hydrolysis upon boiling. Endoribonuclease analysis confirmed that recombinant APE1 from two separate sources (one was prepared by us and the other from Dr. Ian Hickson's lab, University of Oxford) exhibited endoribonuclease activity against c-myc CRD RNA with a distinct preference for the 1751UA dinucleotide (Figure 5B, left panel). Furthermore, when the recombinant APE1 was reduced, denatured with guanidine hydrochloride and renatured, the renatured recombinant APE1 exhibits the same cleavage specificity (lanes 2-4, right panel in Figure 5B) as the native enzyme (lanes 5-7, right panel in Figure 5B) with 1751UA still being the dominant cleavage site.
###end p 46
###begin title 47
Specificity and identification of active residues in APE1 for endoribonuclease activity
###end title 47
###begin p 48
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 184 187 184 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 495 503 495 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 608 616 607 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 719 727 717 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 940 948 937 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1027 1030 1024 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 1291 1299 1288 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
Specific residues Glu96 and His309 have been identified as critical for the AP DNA endonuclease (37,43), exonuclease (44) and RNase H activities of APE1 (39). To examine whether the c-myc CRD RNA-cleaving activity of APE1 requires the same amino acid residues as these nuclease activities of APE1, E96A and H309N APE1 mutant polypeptides were purified under identical purification methods as the wild-type APE1 and tested for endoribonuclease activity under our standard endoribonuclease assay. Figure 6A shows the lack of RNA cleaving activity of the E96A mutant at up to 0.5 mug of the protein (lanes 6-8, Figure 6A). H309N mutant also did not exhibit any endoribonuclease activity at 0.1 and 0.3 mug (lanes 3 and 5, Figure 6A). Interestingly, at a higher concentration (0.5 mug), the H309N mutant cleaved CRD RNA at 1727CA, 1768CA, 1771CA, 1773UA and 1775CA but not at 1757UA, 1751UA, 1747UA and 1742CA (compare lane 4 to lanes 2 and 9, Figure 6A). These results suggest that the endoribonuclease activity of APE1 against c-myc CRD RNA shares, to some extent, common critical amino acid residues with AP DNA endonuclease, RNase H and exonuclease activities. ND42 mutant APE1 missing the first 42 amino acids at the N-terminus demonstrated activity which is similar to the wild-type APE1 (Figure 6A, right panel). This suggests that the N-terminus domain, at least the first 42 amino acids, does not participate in the RNA-cleaving of APE1.
###end p 48
###begin p 49
###xml 152 160 152 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 405 413 405 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
To further confirm specificity of the endoribonuclease activity exhibited by the wild-type and APE1 mutants, we also tested other recombinant proteins. Figure 6B shows that the lack of endoribonuclease activity exhibited by recombinant HADHSC (lanes 4 and 5) and annexin III (lanes 6 and 7) while the wild-type APE1 (lanes 2 and 3) exhibited the typical endoribonuclease activity. Overall, the results in Figure 6 confirms the specificity of the endoribonuclease activity exhibited by the purified wild-type APE1 and absence of RNase A-like contaminants amongst other purified recombinant proteins including the E96A and H309N APE1 mutants.
###end p 49
###begin title 50
APE1 is an endoribonuclease
###end title 50
###begin p 51
###xml 127 129 127 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 145 147 145 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 212 215 212 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 225 233 225 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 323 331 323 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 412 414 412 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 661 664 661 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 859 867 859 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 957 959 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 960 962 960 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
To confirm that APE1 is indeed an endoribonuclease, we challenged the enzyme with two new substrates. First, we tested APE1 on 32P-5'-labeled or 32P-UTP internally labeled RNA corresponding to nts 1730-1766 of c-myc CRD RNA. Figure 7A shows the 5' fragment of the cleavage products generated by APE1 on the 5'-labeled RNA. Figure 7B shows the cleavage products generated when the RNA was internally labeled with 32P-UTP. The corresponding 5' and 3' cleavage fragments were clearly visible indicating the endonucleolytic cleavage of the RNA substrate by APE1. To further confirm this, we tested APE1 on a 5'-labeled DNA oligo corresponding to nts 1742-1757 of c-myc CRD DNA with an incorporation of an uridine at position 1751. As expected, being an endoribonuclease APE1 was only capable of cleaving at position 1751 to generate the 5'-fragment of the oligo (Figure 7C). A recent study has shown that APE1 can cleave AP-site-containing single-stranded RNA (45,46), presumably at the phosphodiester bond immediately 5' to the AP-site. Therefore, it is expected that removal of any bases, including uracil, in single-stranded region of RNA will be susceptible to the abasic RNA-endonuclease activity of APE1.
###end p 51
###begin title 52
###xml 29 32 29 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
APE1 knockdown upregulates c-myc mRNA expression
###end title 52
###begin p 53
###xml 41 44 41 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 693 701 690 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 910 918 907 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
To assess if APE1 can in fact regulate c-myc mRNA expression in cells, we employed siRNA to knockdown APE1 expression in HeLa cells. We previously established that about 80% transfection efficiency can be achieved using Lipofectamine 2000 (33). We used double-stranded Dicer substrate RNAi (dsRNAi) against APE1 (APE1-dsRNAi) based on siRNA sequences used successfully to knockdown APE1 (47). As a negative control, we used DS Scrambled Negative (Control-dsRNAi) with randomly rearranged nucleotides. The effect of APE1-dsRNAi on APE1 protein and mRNA levels was monitored over a 2-day period. The levels of APE1 mRNA were examined using qRT-PCR and normalized against beta-actin mRNA levels. Figure 8B (top panel) shows that APE1 mRNA was reduced by 80% at 24 h and 85% at 48 h. This was accompanied by reduction of APE1 protein of 60% and 70% at 24 and 48 h, respectively, as determined by western analysis (Figure 8A).
###end p 53
###begin p 54
###xml 34 37 34 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 207 210 207 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 247 255 247 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 302 305 302 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 389 392 389 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 545 546 541 542 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 660 663 656 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 705 708 698 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 835 843 825 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F9">Figure 9</xref>
###xml 858 866 848 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F9">Figure 9</xref>
###xml 884 887 874 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 1008 1011 998 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
The effect of APE1 knockdown on c-myc mRNA expression was investigated. Using the same total RNA samples as above, we found 1.7-fold and 4.6-fold increase at 24 and 48 h, respectively, in the steady-state c-myc mRNA levels upon knockdown of APE1 (Figure 8B, bottom panel). To assess whether elevated c-myc mRNA levels upon APE1 knockdown were due to more stable transcript, the decay of c-myc mRNA was examined. We transfected HeLa cells with either APE1-dsRNAi or Control-dsRNAi for 30 h, followed by treatment with 200 muM 5,6-dichloro-1-beta-d-ribobenzimidazole (DRB) to inhibit transcription. Total RNA extracted at various time points were analyzed for c-myc and beta-actin mRNA levels by qRT-PCR. c-myc mRNA level was normalized to beta-actin mRNA level at each time point and then expressed as percentage to the level at 0 min (Figure 9). As shown in Figure 9, the levels of c-myc mRNA in the Control-dsRNAi-treated cells exhibited decay with a half-life of about 30 min. In contrast, the levels of c-myc mRNA in APE1-dsRNAi-treated cells were relatively stable up to 60 min.
###end p 54
###begin title 55
DISCUSSION
###end title 55
###begin p 56
###xml 82 85 82 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 94 102 94 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 167 170 167 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 200 207 200 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 211 212 211 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 213 218 213 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25 B26 B27 B28 B29">25&#8211;29</xref>
###xml 450 451 450 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 682 685 682 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 754 757 754 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 925 928 925 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 937 945 937 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 624 629 <span type="species:ncbi:9606">human</span>
We set the goal of identifying endoribonuclease(s) that are capable of cleaving c-myc CRD RNA in vitro for four specific reasons. First, endonucleolytic cleavage of c-myc mRNA has been shown to occur in vivo (6,7,25-29), implying the presence of the responsible endoribonuclease(s) in cells. Second, many vertebrate mRNA decay intermediates have been detected but only a handful of endoribonucleases that degrade specific mRNAs have been identified (1). Third, our understanding about the role of endoribonucleases in mRNA decay and gene expression in vertebrates is still unclear. Lastly, given that c-Myc is implicated in human cancers, characterization of enzymes that degrade c-myc mRNA may help develop new therapeutic approach via destruction of c-myc mRNA. In this study, we describe the purification and identification of RNase1 as a 17-kDa enzyme and APE1 as a 35-kDa endoribonuclease that are capable of cleaving c-myc CRD RNA in vitro.
###end p 56
###begin p 57
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
###xml 159 162 159 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 171 179 171 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 230 233 230 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 280 283 280 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 295 302 295 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 399 402 399 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 408 416 408 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 647 654 647 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 807 816 807 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figures 1</xref>
###xml 822 823 822 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 926 934 926 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 978 981 978 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 1112 1120 1112 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1009 1014 <span type="species:ncbi:9606">human</span>
###xml 1101 1104 <span type="species:ncbi:10116">rat</span>
RNase1 is a known endoribonuclease, belonging to the RNase A superfamily of ribonucleases (48). Therefore, it is not surprising to see its ability to cleave c-myc CRD RNA in vitro. However, whether RNase1 has a role in cleaving c-myc CRD RNA, and therefore in the regulation of c-myc mRNA level in vivo remains unknown. In addition, APE1 was identified as the 35-kDa endoribonuclease that cleaved c-myc mRNA in vitro. Four findings confirm that APE1 is the protein that contributes to the 35-kDa endoribonuclease activity. (i) Two independent sets of LC/MS-MS data identified APE1 with 32% amino acid sequence coverage and seven matched peptides (Table 1). (ii) As determined by western analysis, APE1 is present in the 30-40-kDa fractions from gel filtration which contained the endoribonuclease activity (Figures 1A and 3). (iii) The endoribonuclease activity was specifically immuno-depleted with APE1 monoclonal antibody (Figure 4). (iv) The cleavage pattern generated on c-myc CRD RNA by the recombinant human APE1 is similar to that generated by the purified native 35-kDa endoribonuclease from rat liver (Figure 5B).
###end p 57
###begin p 58
###xml 480 488 480 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 742 745 742 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 755 763 755 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1041 1049 1041 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
Overall, the endoribonuclease activity of the purified native APE1 and the recombinant APE1 resemble RNase A-like activity, a standard contaminating ribonuclease in RNA studies. However, the following evidence strongly argue against the possibility that the observed endoribonuclease activity of APE1 is due to RNase A contaminants: (i) APE1 antibody which does not cross react with RNase A, specifically immuno-depleted the endoribonuclease activity of the purified native APE1 (Figure 4); (ii) gel filtration used in the last step to partially purify the 35-kDa native APE1 would have excluded any possible RNase A contaminants which are typically below 20 kDa in size; (iii) the cleavage pattern generated by the purified native APE1 on c-myc CRD RNA (Figure 2) and other RNAs are similar but not identical (data not shown) to that generated by RNase A; and (iv) at higher concentrations, other recombinant proteins including mutant APE1 E96A which was purified under identical conditions failed to exhibit any endoribonuclease activity (Figure 6).
###end p 58
###begin p 59
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B50">50</xref>
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 532 534 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 811 813 807 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 888 891 884 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 944 952 940 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1117 1120 1113 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 1305 1308 1301 1304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 468 473 <span type="species:ncbi:9606">human</span>
APE1 has been identified as an unusual, multi-functional protein (37,38). It endonucleolytically cleaves DNA at AP sites, and is a key enzyme in the base excision repair pathway (37). APE1 also provides the major redox activity for AP-1, p53, H1F1alpha and other transcription factors (49). In addition to its AP DNA endonuclease activity, APE1 has 3' -5' DNA exonuclease (50) and 3' phoshodiesterase activities (37). APE1 has also been shown to bind to a fragment of human topoisomerase IIalpha RNA and possesses RNase H activity (39) but the overall biological significance of this function has remained unclear. We have not examined the RNase H activity of recombinant APE1 but the previously partially purified native enzyme which contained both RNase1 and APE1 did not appear to have any RNase H activity (30). Here, we show that recombinant APE1 cleaves specific sequences on the c-myc CRD RNA, namely in between CA and UA dinucleotides (Figure 5B). To our knowledge, this is the first demonstration of a sequence specific endoribonuclease activity intrinsic to APE1. The endoribonuclease activity of APE1 on c-myc CRD RNA appears to share some of the same active site with other nuclease activities of the protein because both E96A and H309N APE1 mutants were inactive or less active in cleaving c-myc CRD RNA.
###end p 59
###begin p 60
###xml 156 159 156 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 191 199 191 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 317 320 317 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 386 389 386 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 426 429 426 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 491 494 491 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 623 626 623 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 679 682 679 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 772 775 772 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 845 848 845 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 920 921 920 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 979 987 979 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1017 1020 1017 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 1109 1112 1109 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 1146 1148 1146 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B51">51</xref>
###xml 1483 1485 1483 1485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B51">51</xref>
To initiate studies on examining the RNA-cleaving potential of APE1 in cells, we used the siRNA technology to transiently knockdown APE1 and then measure c-myc mRNA expression in HeLa cells. Figure 8 shows that transient knockdown of APE1 at the protein and mRNA levels lead to significant increase in steady-state c-myc mRNA. Such observation could be attributed to: (i) more stable c-myc mRNA due to less APE1 in cleaving c-myc mRNA, or/and (ii) decrease in transcriptional repressor of c-myc gene due to less APE1 in keeping some transcriptional factors active. To test the former hypothesis, we assessed the decay of c-myc mRNA upon knockdown of APE1. We found that indeed c-myc mRNA was more stable upon knockdown of APE1 supporting the notion that APE1 can cleave c-myc mRNA and control its abundance in cells. Interestingly, one of the c-myc mRNA endonucleolytic decay intermediates previously detected in cells (7) corresponded to 1727CA, which is a site cleave by APE1 (Figure 2). Our results of increased c-myc mRNA upon knockdown of APE1 is in contrast to a recent report of a modest decrease in c-myc mRNA using micro-array approach (51). This discrepancy could due to the differences in the experimental design. These investigators used stable siRNA-inducible cells that were knockdown for 10 days upon stimulation with siRNA expression and as pointed out by the investigators, compensatory mechanisms and indirect effects may set in for the observed molecular results (51).
###end p 60
###begin p 61
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B52">52</xref>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 695 697 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 892 894 892 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
We have observed stable association of APE1 with YB-1 and hnRNP-H both of which are involved in RNA metabolism (52). In addition to its expected localization to the nucleus, APE1 is also found in the cytoplasm and in some cases, appears to be exclusively located there (38). Such observations and the finding of redistribution of the protein between the nucleus and cytoplasm in some cancers had many researchers baffled for some time (38,49). APE1 has been reported to associate with ribosomes in motor neurons and also possibly in highly proliferative cells including hepatocytes (38), and such observations had led to the speculation that it may have an undefined role in ribosomal function (49). Indeed, a recent report provided strong evidence that the N-terminus of APE1 is physically associated with a number of proteins known to be involved in ribosome biogenesis and RNA processing (46).
###end p 61
###begin p 62
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B53">53</xref>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B54">54</xref>
###xml 621 624 621 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 710 712 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 713 715 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 42 45 <span type="species:ncbi:10116">rat</span>
###xml 332 337 <span type="species:ncbi:9606">human</span>
Interestingly, we have purified APE1 from rat liver polysomal fraction which supports its role in RNA processing. We had earlier shown that APE1 interacts with an RNA-binding protein hnRNP-L in negative regulation of the parathyroid hormone gene (53). Of particular interest is the report that hnRNP-L can regulate the stability of human VEGF mRNA through its AU-rich element during hypoxia (54). Thus, given the evidence provided in this study and the prior evidence, it is tempting to speculate that a previously unknown function of cytoplasmic APE1 is its ability to serve as an endoribonuclease for mRNAs including c-myc mRNA. APE1 has recently been shown to cleave AP-site-containing single-stranded RNA (45,46), providing further support that the enzyme is involved in RNA metabolism in cells.
###end p 62
###begin p 63
###xml 76 79 76 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B55">55</xref>
###xml 228 231 228 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 350 353 350 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
We have previously shown that an RNA-binding protein, CRD-BP, can protect c-myc CRD RNA from degradation by the partially purified native enzyme (55). With the identification of APE1 as a responsible enzyme for the control of c-myc mRNA, we are now in a position to directly investigate if APE1 interacts with CRD-BP in controlling the turnover of c-myc mRNA and other mRNAs in cells.
###end p 63
###begin title 64
FUNDING
###end title 64
###begin p 65
Natural Sciences & Engineering Research Council (227158); the Canadian Cancer Society [to C.H.L, who is a Research Scientist of the National Cancer Institute of Canada (13546)]; T.B was a recipient of UNBC Graduate Entrance and NSERC Canada Graduate Scholarships; W-C.K was a recipient of Pacific Century, Michael Smith Foundation of Health Research Junior Graduate, and NSERC Canada Graduate Scholarships; S-E.K was a recipient of NSERC Undergraduate Summer Research Award; the United States Public Health Service grants (R01 ES08457, R01 CA53791, and P30 ES06676 to S.M. and A.K.M.); and National Institutes of Health/National Cancer Institute grant (CA98664 to T.I.). Funding for open access charge: Natural Sciences & Engineering Research Council Discovery Grant 227158.
###end p 65
###begin p 66
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest statement</italic>
Conflict of interest statement. None declared.
###end p 66
###begin title 67
ACKNOWLEDGEMENTS
###end title 67
###begin p 68
###xml 53 58 <span type="species:ncbi:9606">human</span>
We thank Dr. Ian Hickson for the gift of recombinant human APE1 used in the early studies. We thank Andrea Gorrell and Wai Ming Li for helpful discussion on the manuscript.
###end p 68
###begin title 69
REFERENCES
###end title 69
###begin article-title 70
Regulation of pathways of mRNA destabilization and stabilization
###end article-title 70
###begin article-title 71
Degradation of apolipoprotein II mRNA occurs via endonucleolytic cleavage at 5'-AAU-3'/5'-UAA-3' elements in single-stranded loop domains of the 3'-noncoding region
###end article-title 71
###begin article-title 72
Identification of RNA sequences and structures involved in site-specific cleavage of IGF-II mRNAs
###end article-title 72
###begin article-title 73
Identification of an erythroid-enriched endoribonuclease activity involved in specific mRNA cleavage
###end article-title 73
###begin article-title 74
beta-globin mRNA decay in erythroid cells: UG site-preferred endonucleolytic cleavage that is augmented by a premature termination codon
###end article-title 74
###begin article-title 75
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 69 72 69 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
In vivo generation of 3' and 5'truncated species in the process of c-myc mRNA decay
###end article-title 75
###begin article-title 76
###xml 18 25 18 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 77 85 77 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Identification of in vivo mRNA decay intermediates corresponding to sites of in vitro cleavage by polysomal ribonuclease 1
###end article-title 76
###begin article-title 77
###xml 18 25 18 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Identification of in vivo P-glycoprotein mRNA decay intermediates in normal liver but not in liver tumors
###end article-title 77
###begin article-title 78
###xml 47 64 <span type="species:ncbi:10407">hepatitis B virus</span>
Characterization of nuclear RNases that cleave hepatitis B virus RNA near the La protein binding site
###end article-title 78
###begin article-title 79
###xml 82 92 82 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 82 92 <span type="species:ncbi:7227">Drosophila</span>
Nonsense-mediated messenger RNA decay is initiated by endonucleolytic cleavage in Drosophila
###end article-title 79
###begin article-title 80
RasGAP-associated endoribonuclease G3BP: selective RNA degradation and phosphorylation-dependent localization
###end article-title 80
###begin article-title 81
Cleavage properties of an estrogen-regulated polysomal ribonuclease involved in the destabilization of albumin mRNA
###end article-title 81
###begin article-title 82
###xml 113 129 113 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 16 21 <span type="species:ncbi:9606">human</span>
###xml 113 129 <span type="species:ncbi:562">Escherichia coli</span>
ARD-1 cDNA from human cells encodes a site specific single-stranded endoribonuclease that functionally resembles Escherichia coli RNase E
###end article-title 82
###begin article-title 83
RNase L mediates transient control of the interferon response through modulation of the double-stranded RNA-dependent protein kinase PKR
###end article-title 83
###begin article-title 84
The endoribonuclease activity of mammalian IRE1 autoregulates its mRNA and is required for the unfolded protein response
###end article-title 84
###begin article-title 85
RNAi: finding the elusive endoribonuclease
###end article-title 85
###begin article-title 86
Endonucleolytic RNA cleavage by a eukaryotic exosome
###end article-title 86
###begin article-title 87
The exosome contains domains with specific endoribonuclease, exoribonuclease and cytoplasmic mRNA decay activities
###end article-title 87
###begin article-title 88
###xml 59 64 <span type="species:ncbi:9606">human</span>
SMG6 promotes endonucleolytic cleavage of nonsense mRNA in human cells
###end article-title 88
###begin article-title 89
SMG6 is the catalytic endoribonuclease that cleaves mRNAs containing nonsense codons in metazoan
###end article-title 89
###begin article-title 90
Reconstructing MYC
###end article-title 90
###begin article-title 91
###xml 41 44 41 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
Evidence for a 3'-5' decay pathway for c-myc mRNA in mammalian cells
###end article-title 91
###begin article-title 92
###xml 32 39 32 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitr</italic>
Control of c-myc mRNA half-life in vitro by a protein capable of binding to a coding region determinant
###end article-title 92
###begin article-title 93
###xml 16 19 16 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
Regulation of c-myc mRNA decay by translational pausing in a coding region instability determinant
###end article-title 93
###begin article-title 94
###xml 19 22 19 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
The half-life of c-myc mRNA in growing and serum-stimulated cells: influence of the coding and 3' untranslated regions and role of ribosome translocation
###end article-title 94
###begin article-title 95
The 5' and 3' non-coding sequences of the c-myc gene, required in vitro for its post-transcriptional regulation, are dispensable in vivo
###end article-title 95
###begin article-title 96
###xml 31 34 31 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
The protein coding region of c-myc mRNA contains a sequence that specifies rapid mRNA turnover and induction by protein synthesis inhibitor
###end article-title 96
###begin article-title 97
Coding elements in exons 2 and 3 target c-myc mRNA downregulation during myogenic differentiation
###end article-title 97
###begin article-title 98
###xml 2 5 2 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
c-myc RNA degradation in growing and differentiating cells: possible alternate pathways
###end article-title 98
###begin article-title 99
Purification and characterization of a novel mammalian endoribonuclease
###end article-title 99
###begin article-title 100
###xml 20 23 20 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
Identification of c-myc coding region determinant RNA sequences and structures cleaved by an RNase1-like endoribonuclease
###end article-title 100
###begin article-title 101
###xml 57 62 <span type="species:ncbi:9606">human</span>
Intragenic suppression of an active site mutation in the human apurinic/apyrimidinic endoribonuclease
###end article-title 101
###begin article-title 102
###xml 41 46 <span type="species:ncbi:9606">human</span>
Effective stimulation of growth in MCF-7 human breast cancer cells by inhibition of syntaxin18 by external guide sequence and ribonuclease P
###end article-title 102
###begin article-title 103
Analyzing real-time PCR data by the comparative CT method
###end article-title 103
###begin article-title 104
Cooperation of endo- and exoribonucleases in chloroplast mRNA turnover
###end article-title 104
###begin article-title 105
Annexin A2 is a novel RNA-binding protein
###end article-title 105
###begin article-title 106
Intracellular trafficking and regulation of mammalian AP-endoribonuclease 1 (APE1), and essential DNA repair protein
###end article-title 106
###begin article-title 107
The intracellular localization of APE1/Ref-1: more than a passive phenomenon
###end article-title 107
###begin article-title 108
###xml 33 38 <span type="species:ncbi:9606">human</span>
Site-directed mutagenesis of the human DNA repair enzyme HAP1: identification of residues important for AP endoribonuclease and RNase H activity
###end article-title 108
###begin article-title 109
###xml 84 89 <span type="species:ncbi:9606">human</span>
Characterization of the dimerization process of a domain-swapped dimeric variant of human pancreatic ribonuclease
###end article-title 109
###begin article-title 110
###xml 17 22 <span type="species:ncbi:9606">human</span>
Glycosylation of human pancreatic ribonuclease: differences between normal and tumor states
###end article-title 110
###begin article-title 111
Identification and characterization of mitochondrial abasic (AP)-endoribonuclease in mammalian cells
###end article-title 111
###begin article-title 112
###xml 71 76 <span type="species:ncbi:9606">human</span>
Identification of critical active-site residues in the multifunctional human DNA repair enzyme HAP1
###end article-title 112
###begin article-title 113
###xml 28 33 <span type="species:ncbi:9606">human</span>
The exonuclease activity of human apurinic/apyrimidinic endoribonuclease (APE1)
###end article-title 113
###begin article-title 114
###xml 56 61 <span type="species:ncbi:9606">human</span>
Characterization of abasic endoribonuclease activity of human Ape1 on alternative substrates, as well as effects of ATP and sequence context on AP site incision
###end article-title 114
###begin article-title 115
APE1/Ref-1 interacts with NPM1 within nucleoli and plays a role in the rRNA quality control process
###end article-title 115
###begin article-title 116
Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A
###end article-title 116
###begin article-title 117
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human pancreatic ribonuclease 1: expression and distribution in pancreatic adenocarcinoma
###end article-title 117
###begin article-title 118
Going APE1 over ref-1
###end article-title 118
###begin article-title 119
###xml 30 35 <span type="species:ncbi:9606">human</span>
An exonucleolytic activity of human apurinic/apyrimidinic endoribonuclease on 3' mispaired DNA
###end article-title 119
###begin article-title 120
Genome-wide analysis and proteomic studies reveal APE1/Ref-1 multifunctional role in mammalian cells
###end article-title 120
###begin article-title 121
###xml 19 24 <span type="species:ncbi:9606">human</span>
Regulatory role of human AP-endoribonuclease (APE1/Ref-1) in YB-1-mediated activation of multidrug resistance (MDR1) gene
###end article-title 121
###begin article-title 122
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human AP-endoribonuclease 1 and hnRNP-L interact with a nCaRE-like repressor element in the AP-endoribonuclease 1 promoter
###end article-title 122
###begin article-title 123
###xml 14 19 <span type="species:ncbi:9606">human</span>
Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogenous nuclear ribonucleoprotein L
###end article-title 123
###begin article-title 124
###xml 17 20 17 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myc</italic>
###xml 25 28 25 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDR</italic>
CRD-BP shields c-myc and MDR-1 RNA from endonucleolytic attack by a mammalian endoribonuclease
###end article-title 124

